







2466



chain nodes :

1 2 8 9 10 11 12 15 16 17 18 20 21 22 23 24 25 35 36 39

ring nodes :

3 4 5

chain bonds :

1-2 1-5 1-8 8-9 9-10 10-11 11-12 12-35 15-16 15-20 17-18 21-22 23-24 23-25
35-36 36-39

ring bonds :

3-4 3-5 4-5

exact/norm bonds :

1-2 1-8 8-9 9-10 10-11 11-12 12-35 15-16 15-20 17-18 21-22 23-24 23-25 35-36

exact bonds :

1-5 3-4 3-5 4-5 36-39

G1:O,S

G2:SO2, [*1-*2], [*3-*4], [*5-*6], [*7-*8]

Match level :

1:CLASS 2:CLASS 3:Atom 4:Atom 5:Atom 8:CLASS 9:Atom 10:CLASS 11:Atom 12:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS
25:CLASS 35:CLASS 36:CLASS 39:CLASS

Generic attributes :

9:

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : less than 2

Type of Ring System : Monocyclic

Element Count :

Node 9: Limited

O,00

C,C3-5

N,N1-2

S,S0-1

10/029,871 (patel) (limited to examples)

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2


=> d 14

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR



Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 15:01:45 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 74424 TO ITERATE

1.3% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

3 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 3569

L5 3 SEA SSS SAM L3 AND L1 NOT L2

10/029,871 (patel) (limited to examples)

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7


=> d 19

L9 HAS NO ANSWERS

L6 SCR 1840

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR



Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 AND L6 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 15:03:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13172 TO ITERATE

7.6% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 256573 TO 270307
PROJECTED ANSWERS: 1047 TO 2113

L10 6 SEA SSS SAM L8 AND L6 NOT L7

```

10/029,871 (patel) (limited to examples)

=> ....Testing the current file.... screen
ENTER SCREEN EXPRESSION OR (END):end

=> screen 1006 AND 1840

L11    SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12    SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L13     STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14    QUE L13 AND L11 NOT L12

=> d l14
L14 HAS NO ANSWERS
L11          SCR 1006 AND 1840
L12          SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L13          STR
-
* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
-
Structure attributes must be viewed using STN Express query preparation.
L14          QUE L13 AND L11 NOT L12

=> s l14 sss sam
SAMPLE SEARCH INITIATED 15:08:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 281 TO ITERATE

100.0% PROCESSED      281 ITERATIONS                      0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   4615 TO 6625
PROJECTED ANSWERS:      0 TO 0

L15          0 SEA SSS SAM L13 AND L11 NOT L12

=> ....Testing the current file.... screen
ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L16    SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

```

10/029,871 (patel) (limited to examples)

L17 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L18 STRUCTURE UPLOADED

=> que L18 AND L16 NOT L17

L19 QUE L18 AND L16 NOT L17

=> d l19

L19 HAS NO ANSWERS

L16 SCR 1840

L17 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L18 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L19 QUE L18 AND L16 NOT L17

=> s l19 sss sam

SAMPLE SEARCH INITIATED 15:10:24 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11705 TO ITERATE

8.5% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 227625 TO 240575

PROJECTED ANSWERS: 0 TO 0

L20 0 SEA SSS SAM L18 AND L16 NOT L17

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L21 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L22 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L23 STRUCTURE UPLOADED

=> que L23 AND L21 NOT L22

10/029,871 (patel) (limited to examples)

L24 QUE L23 AND L21 NOT L22

=> d l24

L24 HAS NO ANSWERS

L21 SCR 1840

L22 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L23 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L24 QUE L23 AND L21 NOT L22

=> s l24 sss sam

SAMPLE SEARCH INITIATED 15:12:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11705 TO ITERATE

8.5% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 227625 TO 240575

PROJECTED ANSWERS: 0 TO 0

L25 0 SEA SSS SAM L23 AND L21 NOT L22

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L26 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L27 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L28 STRUCTURE UPLOADED

=> que L28 AND L26 NOT L27

L29 QUE L28 AND L26 NOT L27

=> d l29

L29 HAS NO ANSWERS

L26 SCR 1840

L27 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L28 STR

10/029,871 (patel) (limited to examples)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L29 QUE L28 AND L26 NOT L27

=> s l29 sss sam
SAMPLE SEARCH INITIATED 15:13:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 69927 TO ITERATE

1.4% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 0

L30 0 SEA SSS SAM L28 AND L26 NOT L27

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L31 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L32 SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L33 STRUCTURE UPLOADED

=> que L33 AND L31 NOT L32

L34 QUE L33 AND L31 NOT L32

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L35 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L36 SCREEN CREATED

=>
Uploading C:\STNEXP4\QUERIES\10029871 (patel) (group1).str

L37 STRUCTURE UPLOADED

=> que L37 AND L35 NOT L36

L38 QUE L37 AND L35 NOT L36

=> d l38

L38 HAS NO ANSWERS

L35 SCR 1840

L36 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L37 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L38 QUE L37 AND L35 NOT L36

=> s l38 sss sam

SAMPLE SEARCH INITIATED 15:18:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11705 TO ITERATE

8.5% PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:- ONLINE **COMPLETE**

-

BATCH **COMPLETE**

PROJECTED ITERATIONS: 227625 TO 240575

PROJECTED ANSWERS: 0 TO 0

L39 0 SEA SSS SAM L37 AND L35 NOT L36

=> s l38 sss ful

FULL SEARCH INITIATED 15:18:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 233556 TO ITERATE

100.0% PROCESSED 233556 ITERATIONS

56 ANSWERS

SEARCH TIME: 00.00.08

L40 56 SEA SSS FUL L37 AND L35 NOT L36


=> s l40

L41 7 L40


=> d l41 1-7 bib,ab,hitstr

L41 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:521476 CAPLUS
 DN 137:73286
 TI Preventives for wound adhesion
 IN Kobayashi, Tsuyoshi; Konishi, Atsushi; Yuzawa, Kenji; Takehana, Kenji;
 Iino, Yukio
 PA Ajinomoto Co., Inc., Japan
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053150	A1	20020711	WO 2001-JP11202	20011220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2000-398133	A	20001227		
OS MARPAT 137:73286 AB Disclosed are preventives for wound adhesion contg. specific cyclopropanecarboxylic acid amide compds. or pharmaceutically acceptable salts thereof which are efficacious in preventing wound adhesion. (1S)-N-[6-[4-[[[(1R)-2,2-dimethylcyclopropyl]carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethylcyclopropanecarboxamide (I) was prepd. and tested for its inhibitory activities against NF.kappa.B. I was also effective for preventing cell adhesion in kidney-transplanted Rhesus monkey. IT 318967-14-5P 318967-15-6P 318967-16-7P 318967-20-3P 318967-27-0P 318967-39-4P 318967-44-1P 318967-45-2P 318967-50-9P 318967-51-0P 318967-52-1P 318967-59-8P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of cyclopropanecarboxamides as wound adhesion inhibitors)				
RN 318967-14-5 CAPLUS CN Cyclopropanecarboxamide, N-[6-[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)				




RN 318967-15-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]thio]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-16-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]amino]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-20-3 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 318967-27-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]thio]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-39-4 CAPLUS
 CN Cyclopropanecarboxamide, 2,2-dichloro-N-[6-[4-[[[(2,2-dichlorocyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-44-1 CAPLUS

CN Benzamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 318967-45-2 CAPLUS

CN Benzeneacetamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 318967-50-9 CAPLUS


CN Benzenebutanamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 318967-51-0 CAPLUS


CN Cyclopropanecarboxamide, 2,2-dimethyl-N-[6-[4-[(2-phenylethyl)amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

10/029,871 (patel) (limited to examples)



RN 318967-52-1 CAPLUS


CN Cyclopropanecarboxamide, 2,2-dimethyl-N-[6-[4-[(3-phenylpropyl)amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)



RN 318967-59-8 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[[(1R)-2,2-dimethylcyclopropyl]carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:435864 CAPLUS
 DN 137:362713
 TI APC0576, a novel inhibitor of NF-.kappa.B-dependent gene activation, prevents pro-inflammatory cytokine-induced chemokine production in human endothelial cells
 AU Takehana, Kenji; Konishi, Atsushi; Oonuki, Akiko; Noguchi, Misato; Fujita, Koichi; Iino, Yukio; Kobayashi, Tsuyoshi
 CS Discovery Research Laboratories, Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., Kawasaki-ku, Kawasaki, 210-8681, Japan
 SO Biochemical and Biophysical Research Communications (2002), 293(3), 945-952
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Elsevier Science
 DT Journal
 LA English
 AB Endothelial cells participate in the inflammatory and immune reactions. Endothelial cell activation is a recurrent phenomenon linked to the pathogenesis of diverse human diseases, such as acute and chronic inflammation and cardiovascular disorders. Pro-inflammatory cytokines (e.g., IL-1, TNF) are well-known activators of endothelial cells, since they strongly induce prodn. of chemokines (e.g., IL-8, MCP-1) and cell adhesion mol.s., resulting in an activation of inflammatory transcription factors such as NF-.kappa.B. We have established a cell-based reporter assay for the NF-.kappa.B-dependent gene activation in HUVEC. Using this assay system, we have identified a novel synthetic small mol., APC0576, 5-(((S)-2,2-dimethylcyclopropanecarbonyl)amino)-2-(4-(((S)-2,2-dimethylcyclopropanecarbonyl)amino)phenoxy)pyridine, as an inhibitor of IL-1-induced NF-.kappa.B-dependent gene activation without any adverse effects on the cell viability. APC0576 represses the IL-1-induced release of chemokines (e.g., IL-8, MCP-1) in HUVEC. This inhibitory effect occurred at the level of mRNA expression. Despite having a strong inhibitory effect on the NF-.kappa.B-dependent transcriptional activation, APC0576 does not inhibit the IL-1-induced DNA binding of NF-.kappa.B, degrdn. of I-.kappa.B-.alpha., or phosphorylation of RelA (p65). Although its mol. mechanism of action is not yet clear, APC0576 is a promising therapeutic candidate for diverse diseases involved in the pathogenic endothelial activation.
 IT **318967-58-7**, APC 0576
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (NF-.kappa.B-dependent gene activation inhibitor APC0576 prevents pro-inflammatory cytokine-induced chemokine prodn. in human endothelium)
 RN 318967-58-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[4-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:314913 CAPLUS

DN 136:340689

TI Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis

IN Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 699 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
	WO 2002032872	C1	20020926		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001095986	A5	20020429	AU 2001-95986	20011019
PRAI	JP 2000-320420	A	20001020		
	JP 2000-386195	A	20001220		
	JP 2001-46685	A	20010222		
	WO 2001-JP9221	W	20011019		

OS MARPAT 136:340689

AB N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tgl or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO₂, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH₂)_gSO₂ (g = 1-8), (CH₂)_{fa}CH:CH(CH₂)_{fb} (fa, fb = 0, 1, 2, 3), etc.; and Tgl = a group of the general formula -Eg-CO-NRgl(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rgl = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliph. hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zgl, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having .gtoreq.1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepd. These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed

hypersensitivity. Thus, to soln. of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temp. for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC₅₀ of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT **417714-77-3P 417714-79-5P 417715-00-5P**
417715-01-6P 417715-02-7P 417715-03-8P
417718-10-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea derivs. contg. nitrogenous arom. ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417714-77-3 CAPLUS


CN 2-Propenoic acid, 3-[2-[(cyclopropylcarbonyl)amino]-4-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]phenoxy]-3-pyridinyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 417714-79-5 CAPLUS


CN Cyclopropanecarboxamide, N-(cyclopropylcarbonyl)-N-[3-ethynyl-4-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 417715-00-5 CAPLUS
 CN Cyclobutanecarboxamide, N-[4-[4-[(2-thiazolylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 417715-01-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 417715-02-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[5-bromo-4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 417715-03-8 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-dichloro-4-
 [[(cyclopropylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX
 NAME)



RN 417718-10-6 CAPLUS

CN Cyclobutanecarboxamide, N-[4-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]ph
 enoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 2002:293616 CAPLUS

DN 136:325560

TI Preparation of aliphatic nitrogenous five-membered ring compounds as dipeptidyl peptidase IV inhibitors

IN Yasuda, Kosuke; Morimoto, Hiroshi; Kawanami, Saburo; Hikota, Masataka; Matsumoto, Takeshi; Arakawa, Kenji

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030891	A1	20020418	WO 2001-JP8803	20011005
	W:	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PH, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001094197	A5	20020422	AU 2001-94197	20011005
	JP 2002356471	A2	20021213	JP 2001-309558	20011005
	JP 2002356472	A2	20021213	JP 2001-309559	20011005
PRAI	JP 2000-308528	A	20001006		
	JP 2000-312562	A	20001012		
	JP 2001-99251	A	20010330		
	WO 2001-JP8803	W	20011005		

OS MARPAT 136:325560

AB Aliph. nitrogenous five-membered ring compds., (S)-N-(N-cyclohexylglycyl)pyrrolidine-2-carbonitrile and (R)-N-(N-cyclohexylglycyl)thiazolidine-2-carbonitrile, of the general formula (I) or pharmacol. acceptable salts thereof [wherein A is CH₂ or S; R₁ is hydrogen, lower alkyl, hydroxy-lower alkyl, or lower alkoxy-lower alkyl; X is N(R₃), O, or CO; R₃ is hydrogen or lower alkyl; and R₂ is an optionally substituted mono- or bicyclic hydrocarbonyl or heterocyclyl group or optionally substituted amino] are prepd. These compds. are useful as dipeptidyl peptidase IV inhibitors for the prevention or treatment of diabetes, in particular type II diabetes (no data). Thus, a soln. of (S)-1-bromoacetyl-2-cyanopyrrolidine and N-(5-nitro-2-pyridyl)-trans-1,4-cyclohexanediamine in MeOH/MeCN was stirred at room temp. for 15 h to give, after treatment with 2 N HCl/Et₂O in EtOAc/CHCl₃, (S)-2-cyano-1-[[[trans-4-(5-nitro-2-pyridylamino)cyclohexyl]amino]acetyl]pyrrolidine dihydrochloride.

IT 412287-71-9P 412293-20-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (S)-N-(N-cyclohexylglycyl)pyrrolidine-2-carbonitriles and (R)-N-(N-cyclohexylglycyl)thiazolidine-2-carbonitriles as dipeptidyl peptidase IV inhibitors for prevention or treatment of diabetes)

RN 412287-71-9 CAPLUS

CN Cyclohexanecarboxamide, N-[1-[[trans-4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]cyclohexyl]carbonyl]-4-piperidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 412293-20-0 CAPLUS

CN Cyclohexanecarboxamide, N-[1-[[trans-4-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]cyclohexyl]carbonyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L41 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:31464 CAPLUS
 DN 134:100762
 TI Preparation of pyridine derivatives and medicinal use thereof
 IN Iino, Yukio; Fujita, Kohichi; Kodaira, Arika; Hatanaka, Toshihiro;
 Takehana, Kenji; Kobayashi, Tsuyoshi; Konishi, Atsushi; Yamamoto, Takashi
 PA Ajinomoto Co., Inc., Japan
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002359	A1	20010111	WO 2000-JP4298	20000629
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1193255	A1	20020403	EP 2000-940879	20000629
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000012046	A	20020514	BR 2000-12046 -	20000629
	US 2002133005	A1	20020919	US 2001-29871	20011231
PRAI	JP 1999-187959	A	19990701		
	JP 2000-71706	A	20000315		
	WO 2000-JP4298	W	20000629		
OS	MARPAT 134:100762				
AB	<p>Heterocyclic compds. represented by the following general formula $R1-CO-N(R2)-A-X-B-N(R3)-Y-(CH_2)_n-R4$ [R1 = (un)substituted or cycloalkenyl; R2, R3 = H, alkyl; R4 = (un)substituted alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclyl having .gtoreq.1 heteroatom(s); A = (un)substituted heterocyclic ring; B = (un)substituted arom. or heterocyclic ring; n = 0-6; Y = a bond between atoms, CO, CO2, CONR5, C(S)NR5, SO, SO2 (wherein R5 = H, alkyl); X = a bond between atoms, O, OCHR7, CHR8O, O2C, CO2, OC(S), C(S)O, S, SO, SO2, SCHR9, CHR10S, SC(O), C(O)S, SC(S), C(S)S, SO2 NR11, NR12SO2, NR13, etc.; R7 - R10 = H, alkyl; R11 - R13 = H, alkyl, acyl] or pharmacol. acceptable salts thereof are prepd. These compds. have inhibitory effects on AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor, etc. and are usable as drugs such as antiinflammatory, antirheumatic, antiviral agents, immunosuppressants, cancer metastasis inhibitors, and antiarteriosclerotics. Thus, 2-mercapto-5-nitropyridine was treated with NaH in DMF and then alkylated by 1-bromomethyl-4-nitrobenzene at room temp. for 1.5 h to give 2-(4-nitrobenzylthio)-5-nitropyridine which was reduced by Zn/AcOH in THF at room temp. for 16 h to 2-(4-aminobenzylthio)- 5-aminopyridine and then acylated by 2,2-dimethylcyclopropanecarbonyl chloride in the presence of Et3N in CH2Cl2 at room temp. for 17 h to give 2-(4-(2,2-dimethylcyclopropanecarbonylamino)benzylthio)-5-(2,2- dimethylcyclopropanecarbonylamino)pyridine (I). I in vitro inhibited NF-kappa B activity with IC50 of 0.015 .mu.g/mL in an assay measuring .beta.-galactosidase activity expressed in HUVEC cells and driven by</p>				

IT **318967-19-0P**
 NF-kappa B-binding sequence-fused SV40 T antigen min. promoter.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)
 RN 318967-19-0 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]hydroxymethyl]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




IT **318967-14-5P 318967-15-6P 318967-16-7P**
318967-17-8P 318967-18-9P 318967-20-3P
318967-24-7P 318967-25-8P 318967-26-9P
318967-27-0P 318967-28-1P 318967-29-2P
318967-30-5P 318967-31-6P 318967-32-7P
318967-33-8P 318967-35-0P 318967-36-1P
318967-37-2P 318967-38-3P 318967-39-4P
318967-40-7P 318967-41-8P 318967-42-9P
318967-43-0P 318967-44-1P 318967-45-2P
318967-46-3P 318967-47-4P 318967-48-5P
318967-49-6P 318967-50-9P 318967-51-0P
318967-52-1P 318967-53-2P 318967-54-3P
318967-56-5P 318967-57-6P 318967-58-7P
318967-59-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)
 RN 318967-14-5 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-15-6 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]thio]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-16-7 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]amino]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-17-8 CAPLUS

CN Cyclopropanecarboxamide, N-[5-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]hydroxymethyl]-2-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-18-9 CAPLUS

CN Cyclopropanecarboxamide, N-[5-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]-2-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-20-3 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-24-7 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[2,2-dimethylcyclopropyl]carbonyl]amino]phenyl]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-25-8 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[4-[[2,2-dimethylcyclopropyl]carbonyl]amino]phenyl]methoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-26-9 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[2-[4-[[2,2-dimethylcyclopropyl]carbonyl]amino]phenyl]ethoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-27-0 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[[4-[[2,2-dimethylcyclopropyl]carbonyl]amino]phenyl]methyl]thio]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-28-1 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methyl]-4-piperidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-29-2 CAPLUS

CN Cyclopropanecarboxamide, N-[1-[2-[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]ethyl]-4-piperidinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-30-5 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[3-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-31-6 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[2-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-32-7 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[3-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-33-8 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[[2-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]phenyl]methoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-35-0 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]-3-methylphenoxy]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-36-1 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[[5-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]oxy]phenyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-37-2 CAPLUS
 CN Cyclopropanecarboxamide, N-[6-[4-[(2,2-dimethylcyclopropyl)carbonyl]amino]-3-methylphenoxy]-4-methyl-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 318967-38-3 CAPLUS
 CN Cyclopropanecarboxamide, N,N'-(thiodi-2,5-pyridinediyl)bis[2,2-dimethyl- (9CI) (CA INDEX NAME)]




RN 318967-39-4 CAPLUS
 CN Cyclopropanecarboxamide, 2,2-dichloro-N-[6-[4-[(2,2-dichlorocyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 318967-40-7 CAPLUS
 CN Cyclopropanecarboxamide, 2-methyl-N-[6-[4-[(2-methylcyclopropyl)carbonyl]amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 318967-41-8 CAPLUS
CN Cyclohexanecarboxamide, N-[6-[4-[(cyclohexylcarbonyl)amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 318967-42-9 CAPLUS
CN Cyclohexanecarboxamide, 2-methyl-N-[6-[4-[(2-methylcyclohexyl)carbonyl]amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 318967-43-0 CAPLUS
CN 3-Cyclohexene-1-carboxamide, N-[6-[4-[(3-cyclohexen-1-yl)carbonyl]amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 318967-44-1 CAPLUS
CN Benzamide, N-[4-[5-[(2,2-dimethylcyclopropyl)carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 318967-45-2 CAPLUS
CN Benzeneacetamide, N-[4-[5-[(2,2-dimethylcyclopropyl)carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 318967-46-3 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl- (9CI) (CA INDEX NAME)




RN 318967-47-4 CAPLUS

CN Benzeneacetamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 318967-48-5 CAPLUS

CN Benzeneacetamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 318967-49-6 CAPLUS


CN Benzeneacetamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]-3,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 318967-50-9 CAPLUS
 CN Benzenebutamide, N-[4-[[5-[[2,2-dimethylcyclopropyl]carbonyl]amino]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)




RN 318967-51-0 CAPLUS
 CN Cyclopropanecarboxamide, 2,2-dimethyl-N-[6-[4-[(2-phenylethyl)amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 318967-52-1 CAPLUS
 CN Cyclopropanecarboxamide, 2,2-dimethyl-N-[6-[4-[(3-phenylpropyl)amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 318967-53-2 CAPLUS
 CN Cyclopropanecarboxamide, 2,2-dimethyl-N-[6-[4-[[[(phenylamino)carbonyl]amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 318967-54-3 CAPLUS


CN Cyclopropanecarboxamide, 2,2-dimethyl-N-[6-[4-
[[(phenylamino)thioxomethyl]amino]phenoxy]-3-pyridinyl]- (9CI) (CA INDEX
NAME)



RN 318967-56-5 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]
amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 318967-57-6 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[[(1R)-2,2-dimethylcyclopropyl]carbonyl]
amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 318967-58-7 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[[(1S)-2,2-dimethylcyclopropyl]carbonyl]
amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 318967-59-8 CAPLUS

CN Cyclopropanecarboxamide, N-[6-[4-[[[(1R)-2,2-dimethylcyclopropyl]carbonyl]amino]phenoxy]-3-pyridinyl]-2,2-dimethyl-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **318967-60-1P 318967-64-5P 318967-83-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyridine derivs. as inhibitors of AP-1 activity, NF-kappa B activity, inflammatory cytokine prodn., matrix metalloprotease prodn., expression of inflammatory cell adhesion factor)

RN 318967-60-1 CAPLUS


CN Cyclopropanecarboxamide, N-[6-[4-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]benzoyl]-3-pyridinyl]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 318967-64-5 CAPLUS


CN Carbamic acid, [4-[[[5-[[[(2,2-dimethylcyclopropyl)carbonyl]amino]-2-pyridinyl]oxy]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/029,871 (patel) (limited to examples)



RN 318967-83-8 CAPLUS


CN Carbamic acid, [4-[2-[4-[(2,2-dimethylcyclopropyl)carbonyl]amino]-1-piperidinyl]ethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS
 AN 1995:752361 CAPLUS
 DN 124:8183
 TI Intramolecular hydrogen bonding in acylated 2,2'-bipyridine-3,3'-diamines
 AU Palmans, A. R. A.; Vekemans, J. A. J. M.; Meijer, E. W.
 CS Lab. Org. Chem., Eindhoven Univ. Technol., Eindhoven, 5600 MB, Neth.
 SO Recueil des Travaux Chimiques des Pays-Bas (1995), 114(6), 277-84
 CODEN: RTCPA3; ISSN: 0165-0513
 PB Elsevier
 DT Journal
 LA English
 AB Various di- and monoacylated 2,2'-bipyridine-3,3'-diamines (amides, ureas and acyl ureas) were prepd. and characterized. All mols. show strong intramol. hydrogen bonding between the acyl NH of one ring and the pyridine N-1 of the other (and vice versa), as is deduced from the low field ¹H NMR resonances of the acyl NH protons, which range from .delta. 12.6 to 15.0 ppm in CDCl₃. The nature of the secondary structure of the (di)acylated 2,2'-bipyridine-3,3'-diamines has been investigated using a variety of techniques including variable-temp. ¹H NMR and CD spectroscopy. One example compd. is N,N'-[2,2'-bipyridine]-3,3'-diylbis[hexanamide].
 IT **170970-56-6P 171039-22-8P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (intramol. hydrogen bonding in acylated 2,2'-bipyridine-3,3'-diamines)
 RN 170970-56-6 CAPLUS
 CN 2-Oxabicyclo[2.2.1]heptane-1-carboxamide, N,N'-[2,2'-bipyridine]-3,3'-diylbis[4,7,7-trimethyl-3-oxo-, [1S-[1.alpha.(1'R*,4'S*),4.beta.]]]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me

RN 171039-22-8 CAPLUS
 CN 2-Oxabicyclo[2.2.1]heptane-1-carboxamide, N,N'-[2,2'-bipyridine]-3,3'-
 diylbis[4,7,7-trimethyl-3-oxo-, [1R-[1.alpha.(1R*,4S*),4.beta.]]- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


Me

L41 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:107751 CAPLUS
 DN 120:107751
 TI Preparation of retroreverse pyrrole-amidino oligopeptide anticancer agent analogues
 IN Arcamone, Federico; Lombardi, Paolo; Animati, Fabio
 PA Menarini, A., Industrie Farmaceutiche Riunite S.r.l., Italy; Bristol-Myers Squibb S.p.A.
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9313739	A2	19930722	WO 1993-EP2	19930104
	WO 9313739	A3	19931125		
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9333478	A1	19930803	AU 1993-33478	19930104
	EP 623023	A1	19941109	EP 1993-902141	19930104
	R: DE, ES, FR, GB				
PRAI	IT 1992-MI21		19920110		
	WO 1993-EP2		19930104		
OS	MARPAT 120:107751				
AB	Title compds. I (n = 0-6; A = bond, acyl, arom. heterocycl, X1 = bond, NHCO, CONH; X2, X3 = CONH, NHCO; R1, R2 = oxiranomethyl, 1-aziridinomethyl, (substituted) C2-4 alkyl, C2-4 alkoxyhalo, R4O2SO wherein R4 = C1-4 alkyl, Ph; R1 = H, R2 = R3(CH2)mCO wherein R3 = halo, oxiranyl, methyloxiranyl, aziridinyl, cyclopropyl, (substituted) C2-6 alkenyl, etc.) useful as anticancer and antiviral agents (no data), are prepd. 4-(H2N)C6H4N(HOCH2CH2)2 in MeOH was added to a C6H6 soln. of 1-methyl-2-carbomethoxy-4-pyrrolecarboxylic acid to give Me 1-methyl-4-[4-[N,N-bis(2-hydroxyethyl)amino]benzylaminocarbonyl]pyrrole-2-carboxylate which was saponified to the free acid which was converted to bis(2-chloroethyl) deriv. which in DMF was added to 1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamidopropionamidino-HCl, N-hydroxybenzotriazole, 1,8-bis(dimethylamino)naphthalene and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide to give the title I (n = 0, A = p-phenylene, X1 = HNCO, X2 = X3 = CONH, R1 = R2 = ClCH2CH2).HCl.				
IT	150691-34-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as anticancer and antiviral agent)				
RN	150691-34-2 CAPLUS				
CN	1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[(cyclopropylcarbonyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)				

10/029,871 (patel) (limited to examples)

PAGE 1-A




66

PAGE 2-A

● HCl

PAGE 1-A



PAGE 2-A

● HCl

L41 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:107751 CAPLUS
 DN 120:107751
 TI Preparation of retroreverse pyrrole-amidino oligopeptide anticancer agent analogues
 IN Arcamone, Federico; Lombardi, Paolo; Animati, Fabio
 PA Menarini, A., Industrie Farmaceutiche Riunite S.r.l., Italy; Bristol-Myers Squibb S.p.A.
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9313739	A2	19930722	WO 1993-EP2	19930104
	WO 9313739	A3	19931125		
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	AU 9333478	A1	19930803	AU 1993-33478	19930104
	EP 623023	A1	19941109	EP 1993-902141	19930104
	R: DE, ES, FR, GB				
PRAI	IT 1992-MI21		19920110		
	WO 1993-EP2		19930104		
OS	MARPAT 120:107751				
AB	Title compds. I (n = 0-6; A = bond, acyl, arom. heterocycl, X1 = bond, NHCO, CONH; X2, X3 = CONH, NHCO; R1, R2 = oxiranomethyl, 1-aziridinomethyl, (substituted) C2-4 alkyl, C2-4 alkoxyhalo, R4O2SO wherein R4 = C1-4 alkyl, Ph; R1 = H, R2 = R3(CH2)mCO wherein R3 = halo, oxiranyl, methyloxiranyl, aziridinyl, cyclopropyl, (substituted) C2-6 alkenyl, etc.) useful as anticancer and antiviral agents (no data), are prepd. 4-(H2N)C6H4N(HOCH2CH2)2 in MeOH was added to a C6H6 soln. of 1-methyl-2-carbomethoxy-4-pyrrolecarboxylic acid to give Me 1-methyl-4-[4-[N,N-bis(2-hydroxyethyl)amino]benzeneaminocarbonyl]pyrrole-2-carboxylate which was saponified to the free acid which was converted to bis(2-chloroethyl deriv. which in DMF was added to 1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamidopropionamidino-HCl, N-hydroxybenzotriazole, 1,8-bis(dimethylamino)naphthalene and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide to give the title I (n = 0, A = p-phenylene, X1 = HNCO, X2 = X3 = CONH, R1 = R2 = ClCH2CH2).HCl.				
IT	150691-34-2P RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as anticancer and antiviral agent)				
RN	150691-34-2 CAPLUS				
CN	1H-Pyrrole-2,4-dicarboxamide, N2-(3-amino-3-iminopropyl)-N4-[4-[[[4-[(cyclopropylcarbonyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrol-2-yl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)				

10/029,871 (patel) (limited to examples)

=> d his

(FILE 'HOME' ENTERED AT 15:01:10 ON 13 MAY 2003)

FILE 'REGISTRY' ENTERED AT 15:01:14 ON 13 MAY 2003

L1 SCREEN 1840
L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3 STRUCTURE UPLOADED
L4 QUE L3 AND L1 NOT L2
L5 3 S L4 SSS SAM
L6 SCREEN 1840
L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8 STRUCTURE UPLOADED
L9 QUE L8 AND L6 NOT L7
L10 6 S L9 SSS SAM
L11 SCREEN 1006 AND 1840
L12 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L13 STRUCTURE UPLOADED
L14 QUE L13 AND L11 NOT L12
L15 0 S L14 SSS SAM
L16 SCREEN 1840
L17 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L18 STRUCTURE UPLOADED
L19 QUE L18 AND L16 NOT L17
L20 0 S L19 SSS SAM
L21 SCREEN 1840
L22 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L23 STRUCTURE UPLOADED
L24 QUE L23 AND L21 NOT L22
L25 0 S L24 SSS SAM
L26 SCREEN 1840
L27 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L28 STRUCTURE UPLOADED
L29 QUE L28 AND L26 NOT L27
L30 0 S L29 SSS SAM
L31 SCREEN 1840
L32 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L33 STRUCTURE UPLOADED
L34 QUE L33 AND L31 NOT L32
L35 SCREEN 1840
L36 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L37 STRUCTURE UPLOADED
L38 QUE L37 AND L35 NOT L36
L39 0 S L38 SSS SAM
L40 56 S L38 SSS FUL

FILE 'CAPLUS' ENTERED AT 15:18:27 ON 13 MAY 2003

L41 7 S L40

FILE 'CAOLD' ENTERED AT 15:19:04 ON 13 MAY 2003

=> s 140

L42 0 L40

=> log y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.40


192.13

10/029,871 (patel) (limited to examples)

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-4.56

STN INTERNATIONAL LOGOFF AT 15:19:24 ON 13 MAY 2003

C:\STNEXP4\QUERIES\10029871 (patel) (subgenus2).s



chain nodes :

1 2 3 4 5 6 7 8 9 24 25 26 27 28 29 30 31 33 34 49 54 55

ring nodes :

10 11 12 13 14 15 16

ring/chain nodes :

44

chain bonds :

1-5 1-49 2-3 2-49 3-4 4-9 5-6 6-7 6-8 9-44 24-25 26-27 26-28 29-30 29-31
33-34

ring bonds :

10-11 10-12 11-12 13-14 13-16 14-15 15-16

exact/norm bonds :

1-5 1-49 2-3 2-49 3-4 4-9 5-6 6-7 6-8 10-11 10-12 11-12 13-14 13-16 14-15
15-16 24-25 26-27 26-28 29-30 29-31 33-34

exact bonds :

9-44

G1:[*1],[*2]

G2:O,S

G3:SO2,[*3-*4],[*5-*6],[*7-*8],[*9-*10]

G4:C,O,S,N

G5:[*11-*12],[*13-*14]

Match level :

1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS 34:CLASS 44:CLASS 49:CLASS
54:CLASS

55:CLASS

Generic attributes :

1:

Type of Ring System : Monocyclic

55:

Saturation : Unsaturated

Element Count :

Node 1: Limited

N,N1

Node 2: Limited

C,C6

10/029,871 (patel)

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (subgenus2).str

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d l4

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam

SAMPLE SEARCH INITIATED 08:02:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 69937 TO ITERATE

1.4* PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**

PROJECTED ITERATIONS: EXCEEDS 1000000

PROJECTED ANSWERS: EXCEEDS 0

L5 0 SEA SSS SAM L3 AND L1 NOT L2

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L6 SCREEN CREATED

10/029,871 (patel)

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (subgenus2).str

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840

L10 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L11 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\10029871 (patel) (subgenus2).str

L12 STRUCTURE UPLOADED

=> que L12 AND L10 NOT L11

L13 QUE L12 AND L10 NOT L11

=> d l13

L13 HAS NO ANSWERS

L10 SCR 1840

L11 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L12 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L13 QUE L12 AND L10 NOT L11

=> s l13 sss sam

SAMPLE SEARCH INITIATED 08:11:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 69937 TO ITERATE

1.4* PROCESSED 1000 ITERATIONS

0 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS: EXCEEDS 1000000

10/029,871 (patel)

PROJECTED ANSWERS: EXCEEDS 0

L14 0 SEA SSS SAM L12 AND L10 NOT L11

=> s l13 sss ful

FULL SEARCH INITIATED 08:11:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 28.6* PROCESSED 400000 ITERATIONS

376 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.38

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**

BATCH **INCOMPLETE**

PROJECTED ITERATIONS: EXCEEDS 1000000

PROJECTED ANSWERS: EXCEEDS 1204

L15 376 SEA SSS FUL L12 AND L10 NOT L11

=> s l15


L16 27 L15

=> d l16 1-27 bib,ab,hitstr

L16 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:282567 CAPLUS
 DN 138:304297
 TI Preparation of thiazolyl substituted aminopyrimidines as plant protection agents
 IN Mueller, Urs; Eberle, Martin; Pillonel, Christian; Lutz, William; Stanetty, Peter
 PA Syngenta Participations Ag, Switz.
 SO PCT Int. Appl., 128 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003029249	A1	20030410	WO 2002-IB3868	20020919
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2001-23589	A	20011001		
AB	The title compds. [I; R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, haloalkyl, etc.; NR1R2 = (un)substituted (un)satd. ring which may contain O or S as a ring member, or form N:CR9NR10R11; R3 = H, halo, alkyl; R4 = H, alkyl, haloalkyl, etc.; R5 = H, OH, halo, etc.; R6 = H, alkyl, haloalkyl; R7 = (un)substituted thienyl, pyridyl, aryl; R8 = H, alkyl, alkenyl, etc.; R9 = H, alkyl, haloalkyl, etc.; R10 = alkyl, haloalkyl, alkoxyalkyl, etc.; R11 = alkyl, cycloalkyl, aryl, etc.], useful as fungicides, were prepd. Thus, a multi-step synthesis of I [NR1R2 = N:C(Me)NMe2; R3-R6 = H; R7 = Ph; R8 = H], starting from 4-methyl-2-methylthiopyrimidine and Me benzoate, was given. The compds. I showed good activity in twelve different tests (biol. data given).				
IT	509086-98-0P RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of thiazolyl substituted aminopyrimidines as plant protection agents)				
RN	509086-98-0 CAPLUS				
CN	Cyclopropanecarboxamide, N-[4-phenyl-5-[2-(phenylamino)-4-pyrimidinyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)				

NHPh



10/029,871 (patel)


RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:282325 CAPLUS
 TI Preparation of quinazoline-2,4-diamines as MCH receptor antagonists
 IN Sekiguchi, Yoshinori; Kanuma, Kosuke; Omodera, Katsunori; Tran, Thuy-anh;
 Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
 PA Taisho Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 1171 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003028641	A2	20030410	WO 2002-US31059	20020930
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-326463P	P	20011001		
	US 2001-326758P	P	20011002		
AB	The title compds. QLYR1[Q = I, C(:NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl), etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression, were prepd. Thus, hydrogenation of benzyl cis-[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexylmethyl]carbamate followed by reacting the resulting intermediate with 4-bromo-2-trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 34% cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.				
IT	510734-17-5P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of quinazoline-2,4-diamines as MCH receptor antagonists)				
RN	510734-17-5 CAPLUS				
CN	Benzamide, 4-bromo-N-[1-[4-(dimethylamino)-2-quinazolinyl]-4-piperidinyl]-2-(trifluoromethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)				



● HCl

L16 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:242303 CAPLUS
 DN 138:271541
 TI Preparation of 2-phenyl-3-heteroarylpropionic acid derivatives as VLA-4
 and/or LPAM-1 antagonist
 IN Ikegami, Satoru; Hoshina, Yoichiro
 PA Kaken Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024933	A1	20030327	WO 2002-JP8921	20020903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2001-276371 A 20010912

OS MARPAT 138:271541

AB The title compds. I [wherein Het = arom. heterocycle; X1-X5 =
 independently H, inorg. group, hydrocarbyl, Y-hydrocarbyl, heteroaryl,
 (un)substituted amino, OCO-amino, or CO-amino; Y = O, S, OCO, CO, CO2,
 SO2, or SO; or two of X1, X2, and X3 may form OCH2O, or benzene ring with
 the neighboring carbon atoms] and their salts thereof are prepd. as
 .alpha.4.beta.1-integrin (VLA-4) and/or antigen LPAM-1 antagonist. For
 example, the compd. II was prepd. in a multi-step synthesis in good yield.
 II showed inhibiting activity against cell adhesion in guinea pig with
 IC50 of 1.2 nM.

IT **503275-97-6P 503275-98-7P 503275-99-8P**

503276-00-4P 503276-01-5P 503276-02-6P


503276-03-7P 503276-04-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; prepn. of phenyl(heteroaryl)propionic acid derivs. as
 VLA-4 and/or LPAM-1 antagonist)


RN 503275-97-6 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[3-[(2,2-
 dimethyl-1-oxopropyl)(2-methylpropyl)amino]-4-methoxyphenyl]- (9CI) (CA
 INDEX NAME)




RN 503275-98-7 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[4-methoxy-3-[(2-methyl-1-oxopropyl)(2-methylpropyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 503275-99-8 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[3-[(2-ethyl-1-oxobutyl)(2-methylpropyl)amino]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 503276-00-4 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[4-methoxy-3-[(2-methylpropyl)[(phenylmethoxy)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 503276-01-5 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[4-ethoxy-3-[(2-methyl-1-oxopropyl)(2-methylpropyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 503276-02-6 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[3-[(2,2-dimethyl-1-oxopropyl)(2-methylpropyl)amino]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 503276-03-7 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[4-ethoxy-3-[(2-ethyl-1-oxobutyl)(2-methylpropyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 503276-04-8 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[(2,6-dichlorobenzoyl)amino]-.alpha.-[4-ethoxy-3-[(2-methylpropyl)[(phenylmethoxy)carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 503276-09-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of phenyl(heteroaryl)propionic acid derivs. as VLA-4 and/or LPAM-1 antagonist)

RN 503276-09-3 CAPLUS

CN 3-Pyridinepropanoic acid, 6-[bis(2,6-dichlorobenzoyl)amino]-.alpha.-[3-[(2,2-dimethyl-1-oxopropyl)(2-methylpropyl)amino]-4-methoxyphenyl]-, ethyl ester (9CI) (CA INDEX NAME)



10/029,871 (patel)

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2003:214966 CAPLUS

DN 138:245492

TI Color photographic materials with good color reproducibility, image processing by scanning, and scanners

IN Noguchi, Takashi; Hosokawa, Junichiro; Uchida, Michihiro; Shimada, Yasuhiro

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 56 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003084402	A2	20030319	JP 2001-280367	20010914
PRAI	JP 2001-280367		20010914		

AB The photog. material has .gtoreq.4 photosensitive layers with different spectral sensitivity curves in the visible region and covariance between the sensitivity curves .ltoreq.0.5, which develop colors with different spectral absorption curves. The 4th photosensitive layer may be a cyan-sensitive layer contg. IR couplers.


IT **501953-59-9 501953-62-4**

RL: TEM (Technical or engineered material use); USES (Uses)

(IR coupler; color photog. films having cyan-sensitive layers contg. IR couplers with good color reproducibility for digital scanning)


RN 501953-59-9 CAPLUS

CN Propanoic acid, 2-[[3-[[[4-[4-(acetylamino)phenyl]-5-tetradecyl-2-thiazolyl]amino]carbonyl]-4-hydroxy-8-[(trifluoroacetyl)amino]-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



RN 501953-62-4 CAPLUS


CN Acetic acid, [[2-[[4-hydroxy-8-[(methoxycarbonyl)amino]-3-[[[5-[[2-(octadecyloxy)benzoyl]amino]-4-(trifluoromethyl)-2-thiazolyl]amino]carbonyl]-1-naphthalenyl]oxy]ethyl]thio]- (9CI) (CA INDEX NAME)



L16 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2003:42101 CAPLUS
 DN 138:106502
 TI Preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MTP)
 IN Priepke, Henning; Huel, Norbert; Dahmann, Georg; Thomas, Leo; Mark, Michael
 PA Boehringer Ingelheim Pharma K.-G., Germany
 SO PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004020	A1	20030116	WO 2002-EP7215	20020629
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10132686	A1	20030116	DE 2001-10132686	20010705
	US 2003073836	A1	20030417	US 2002-187860	20020702
PRAI	DE 2001-10132686	A	20010705		
	US 2001-304584P	P	20010711		
OS	MARPAT 138:106502				
AB	Title compds. I [X1 = CR1; X2 = CR2; X3 = CR3; X4 = CR4; with 1-2 of the groups being a N-atom; R1, R2, R3, R4 = H, halo, alkyl, etc.; A = O, S, NH, etc.; R8 = (un)substituted Ph, 1-naphthyl, 2-naphthyl, etc.; R5 = H, (un)substituted alkyl; R6 = H, alkyl; R7 = (un)substituted alkyl; Y = 1-2 carbon atom(s) bound to (un)substituted 5-membered heteroaryl] and their pharmaceutically acceptable salts were prepd. For example, coupling of acid II, e.g., prepd. from 4-hydrazinobenzonitrile in 5-steps, and 4-phenylbenzylamine afforded biphenylcarboxylic acid amide III in 86% yield. In triglyceride transfer protein inhibition studies, compds. I exhibited IC50 values .ltoreq. 100.mu.M. Compds. I are claimed useful as inhibitors of microsomal triglyceride transfer protein (MTP) for the treatment of atherosclerosis.				
IT	486434-55-3P , N-(4-Benzoylamino)phenylmethyl)-2-(biphenyl-2-carbonylamino)thiazol-4-carboxamide 486434-98-4P 486435-54-5P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; prepn. of biphenylcarboxylic acid amides as microsomal triglyceride transfer protein (MTP) inhibitors)				
RN	486434-55-3 CAPLUS				
CN	4-Thiazolecarboxamide, N-[[4-(benzoylamino)phenyl]methyl]-2-[[[1,1'-biphenyl]-2-ylcarbonyl]amino]- (9CI) (CA INDEX NAME)				

10/029,871 (patel)




RN 486434-98-4 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[[4-(benzoylamino)phenyl]methyl]-1-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 486435-54-5 CAPLUS

CN 4-Pyrimidinecarboxamide, N-[4-[[[1-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-1H-pyrrol-2-yl]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2002:964381 CAPLUS

DN 138:39538

TI Sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa

IN Chan, Chuen; Hamblin, Julie Nicole; Kelly, Henry Andreson; King, Nigel

Paul; Mason, Andrew McMurtrie; Patel, Vipulkumar Kantibhai; Senger,

Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Weston, Helen

Elisabeth; Whitworth, Caroline; Young, Robert John

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 210 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002100886	A1	20021219	WO 2002-GB2586	20020606
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2001-14004 A 20010608

OS MARPAT 138:39538

AB Title compds. I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, Ph, heterocyclyl; R2 = alkyl, CF3; NR3R4 = (un)substituted heterocyclic; R5 = fused bicyclic, (un)substituted Ph, heteroarom., aralkyl, heteroarylalkyl] were prep'd. for use in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated (no data). Thus, Z-L-Met-OH was treated with H-L-Ala-OCMe2 and the dipeptide was cyclized with acid ion exchange resin to give tert.-Bu (2S)-2-[(3S)-3-benzyloxycarbonylamino-2-oxopyrrolidin-1-yl]propanoate, which was deblocked and sulfonylated with 6-chloro-2-naphthalenesulfonyl chloride, followed by ester hydrolysis and amidation with morpholine to give the sulfonamide II.

IT **478639-01-9P 478639-70-2P 478641-07-5P****478641-93-9P 478642-10-3P 478642-12-5P****478642-55-6P 478643-04-8P 478647-29-9P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)

RN 478639-01-9 CAPLUS

CN Benzamide, N-[1-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/029,871 (patel)



RN 478639-70-2 CAPLUS

CN Cyclopentanecarboxamide, N-[1-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-07-5 CAPLUS

CN Benzamide, N-[1-[(2R)-2-[(3S)-3-[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-93-9 CAPLUS

CN Benzamide, N-[1-[(2R)-2-[(3S)-3-[[6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-10-3 CAPLUS

10/029,871 (patel)

CN Benzamide, N-[1-[(2R)-2-[(3S)-3-[[6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-12-5 CAPLUS

CN Benzamide, N-[1-[(2R)-2-[(3S)-3-[[6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-55-6 CAPLUS

CN Benzamide, N-[1-[(2R)-2-[(3R)-3-[[6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478643-04-8 CAPLUS

CN Benzamide, N-[(3R)-1-[(2R)-2-[(3R)-3-[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478647-29-9 CAPLUS

CN Benzamide, N-[(3S)-1-[(2R)-2-[(3R)-3-[[6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:946279 CAPLUS
 DN 138:24719
 TI Preparation of 1,4-disubstituted benzo-fused cycloalkyl ureas as
 antiinflammatory agents
 IN Cirillo, Pier F.; Hickey, Eugene R.
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098869	A2	20021212	WO 2002-US16720	20020524
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
	CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2001-295909P	P	20010605		
OS	CASREACT 138:24719; MARPAT 138:24719				
AB	The title compds. [I; n = 1-5; cycloalkyl can be optionally substituted by 1-2 R1 or R2; X = O; p = 0-1; z = 0-1; A = fused (un)satd. (un)substituted ring contg. 3-5 carbon atoms; L = a bond, O, NH, CO, CS, etc.; J = CH2, (CH2)2, CH2CHMe, CH2CHOH, CHOH, CO; Q = (un)substituted Ph, naphthyl, pyridinyl, etc.; R1 = (un)substituted Ph, CH2Ph, naphthyl, etc.; R2 = alkyl, haloalkyl, acyl, etc.], useful for treating a cytokine mediated diseases (no biol. data), were prepd. Thus, reacting 4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-ylamine with trans-2-phenylcyclopropyl isocyanate in THF afforded II.				
IT	478044-91-6P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of 1,4-disubstituted benzo-fused cycloalkyl ureas as antiinflammatory agents)				
RN	478044-91-6 CAPLUS				
CN	Benzamide, N-[4-[[4-[[[(2-cyclohexylcyclopropyl)amino]carbonyl]amino]-1-naphthalenyl]oxy]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)				

PAGE 1-A




PAGE 2-A




L16 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:946251 CAPLUS
 DN 138:24722
 TI Preparation of biphenylcarboxamides as apolipoprotein B secretion
 inhibitors and hypolipemics
 IN Annaka, Masayuki; Kusama, Mari; Kamaya, Hiroshi; Tanaka, Keiko; Igarashi,
 Shigeki
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098839	A1	20021212	WO 2002-JP5358	20020531
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CG, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003048872	A2	20030221	JP 2002-155743	20020529
PRAI JP 2001-165983	A	20010601		
OS MARPAT 138:24722				
AB The title compds. I [R1 is optionally halogenated lower alkyl or the like; R2 is hydrogen, carboxyl, lower alkoxy carbonyl, lower alkoxy, or the like; Y is CH or N; R3 is a group represented by the general formula (CH ₂) _p NHR ₈ or the like; p is an integer (1 to 6); R ₈ is org. moiety; and R ₄ is hydrogen or halogeno], useful as apolipoprotein B secretion inhibitors and hypolipemics (no data), are prepd. Processes for prepg. I are disclosed. For example, 1-(4-(2-(4-trifluoromethylphenyl)benzoylamino)phenyl)-3-(2- pyrimidinyl)aminopyrrolidine was prepd.				
IT 478034-38-7P 478034-85-4P RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of biphenylcarboxamides as apolipoprotein B secretion inhibitors and hypolipemics)				
RN 478034-38-7	CAPLUS			
CN Carbamic acid, [1-[5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2- yl]carbonylamino]-2-pyridinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				




RN 478034-85-4 CAPLUS
 CN Carbamic acid, [1-[5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:870388 CAPLUS
 DN 138:72875
 TI C3-Symmetrical Supramolecular Architectures: Fibers and Organic Gels from
 Discotic Trisamides and Trisureas
 AU van Gorp, Judith J.; Vekemans, Jef A. J. M.; Meijer, E. W.
 CS Laboratory of Macromolecular and Organic Chemistry, Eindhoven University
 of Technology, Eindhoven, 5600 MB, Neth.
 SO Journal of the American Chemical Society (2002), 124(49), 14759-14769
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 138:72875
 AB Hydrogen bonded C3-sym. mols. that assoc. into supramol. stacks are
 described. Structural mutation on these mols. has been performed to
 elucidate the contribution of the different secondary interactions
 (hydrogen bonding, .pi.-.pi. stacking) to the self-assembly of the disks
 into chiral stacks. Twelve C3-sym. mols. have been investigated, six of
 which contain three central amide functionalities (1a-f) and six of which
 contain three central urea groups (2a-f). Peripheral groups of the disks
 are "small", "medium", or "large", half of them being achiral and the
 other half being chiral, to enable investigation of the supramol.
 architectures with CD spectroscopy. In all of the cases, elongated,
 helical stacks are formed in apolar soln., except for the "medium" amide
 disks 1c/d. The elongated stacks of the C3-sym. disks form gels, which
 are visualized by AFM and SANS, and this confirms the directionality of
 the interactions. For the "large" urea disk, 2f, fibers with a length of
 up to 2 .mu.m are obsd. Temp. dependent and "sergeants-and-soldiers" CD
 measurements reveal that the urea stacks are much more rigid than the
 corresponding amide ones. In case of the "medium" urea disks, 2c/d, a
 true rigid rod, is formed. Where amide disks immediately reach their
 thermodyn. equil., kinetic factors seem to govern urea aggregation. In a
 no. of expts. aimed at reversibility with the urea stacks, hysteresis is
 obsd., implying that these urea disks initially form a poorly defined
 stack, which subsequently transforms slowly into a well-defined, chiral
 architecture.
 IT **480445-01-0P 480445-06-5P 480445-07-6P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (C3-Sym. supramol. architectures of fibers and org. gels from discotic
 trisamides and triureas)
 RN 480445-01-0 CAPLUS
 CN 1,3,5-Benzenetricarboxamide, N,N'-bis[3'-[[3,4,5-
 tris(dodecyloxy)benzoyl]amino][2,2'-bipyridin]-3-yl]-N''-[3'-[[[3,4,5-
 tris(dodecyloxy)phenyl]amino]carbonyl][2,2'-bipyridin]-3-yl]- (9CI) (CA
 INDEX NAME)



PAGE 1-B



PAGE 2-A




RN 480445-06-5 CAPLUS
CN [2,2'-Bipyridine]-3-carboxamide, 3'--[[[3,5-bis[[[3'-[3,4,5-tris(dodecyloxy)benzoyl]amino][2,2'-bipyridin]-3-yl]amino]carbonyl]amino]phenyl]amino]carbonyl]amino]-N-[3,4,5-


10/029,871 (patel)

tris(dodecyloxy)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A

$\text{O}=\text{C}$

$\text{Me}-(\text{CH}_2)_{11}-\text{O}$ $\text{O}-(\text{CH}_2)_{11}-\text{Me}$
 $\text{O}-(\text{CH}_2)_{11}-\text{Me}$


10/029,871 (patel)

RN 480445-07-6 CAPLUS


CN Benzamide, N,N',N''-[1,3,5-benzenetriyltris(iminocarbonylimino[2,2'-bipyridine]-3',3'-diyl)]tris[3,4,5-tris[[3,7-dimethyloctyl]oxy]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



10/029,871 (patel)


PAGE 2-B

S

CHMe₂

Me

RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT




Page 30

10/029,871 (patel)


CN Cholest-5-en-3-ol (3.beta.)-, [4-[[4-[[4-(1,1-dimethylethyl)benzoyl]amino]-2-oxo-1(2H)-pyrimidinyl]methyl]phenyl]carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2002:814126 CAPLUS

DN 137:325327

TI Preparation of thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines as inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

IN Cao, Jingrong; Green, Jeremy; Moon, Young-Choon; Wang, Jian; Ledebuer, Mark; Harrington, Edmund; Gao, Huai

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 137 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083667	A2	20021024	WO 2002-US11570	20020410
	WO 2002083667	A3	20030103		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
PRAI	US 2001-283621P	P	20010413		
	US 2001-292974P	P	20010523		
	US 2001-329440P	P	20011015		
OS	MARPAT 137:325327				
AB	The present invention provides thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines (shown as I, e.g. 2-methylsulfanyl-5-(2-phenylaminopyrimidin-4-yl)-4-(4-chlorophenyl)thiophene-3-carbonitrile): or a pharmaceutically acceptable deriv. thereof, wherein A, B, Ra, R1, R2, R3 and R4 are as described in the specification. These compds. are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli; Lck and Src kinase. The invention also provides pharmaceutical compns. comprising the inhibitors of the invention and methods of using those compns. in the treatment and prevention of various disorders. Although the methods of prepn. are not claimed, 42 example preps. of intermediates and I are included. Results of JNK, Src and Lck inhibition are tabulated for many I.				
IT	473531-17-8P 473532-24-0P 473532-36-4P 473532-56-8P 473532-67-1P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug candidate; prepn. of thienyl-substituted pyrimidinyl, pyridinyl and triazinyl amines as inhibitors of JNK and other protein kinases)				
RN	473531-17-8 CAPLUS				
CN	3-Thiophenecarboxamide, 2-[2-(benzoylamino)-4-pyrimidinyl]-4-(ethylamino)-N-(phenylmethyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)				




RN 473532-24-0 CAPLUS

CN 3-Thiophenecarboxamide, 2-[2-(benzoylamino)-4-pyridinyl]-4-(ethylamino)-N-(phenylmethyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 473532-36-4 CAPLUS


CN 3-Thiophenecarboxamide, 4-[2-(benzoylamino)-4-pyridinyl]-2-(ethylamino)-N-(phenylmethyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 473532-56-8 CAPLUS

CN 3-Thiophenecarboxamide, 2-[3-(benzoylamino)-1,2,4-triazin-5-yl]-4-(ethylamino)-N-(phenylmethyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)

10/029,871 (patel)



RN 473532-67-1 CAPLUS
CN 3-Thiophenecarboxamide, 4-[3-(benzoylamino)-1,2,4-triazin-5-yl]-2-(ethylamino)-N-(phenylmethyl)-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



L16 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:615589 CAPLUS
 DN 137:169545
 TI Preparation of 2-acylaminothiazole derivatives or their salts as promoters of megakaryocyte colony formation
 IN Koshio, Hiroyuki; Kimizuka, Tetsuya; Sugasawa, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Suzuki, Kenichi; Abe, Masaki
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062775	A1	20020815	WO 2002-JP755	20020131
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	JP 2001-26955	A	20010202		

OS MARPAT 137:169545


AB The title compds. [I; Ar = Ph or pyridinyl optionally substituted by .gtoreq.1 group(s) selected from lower alkyl, lower alkylcarbonyl, lower alkoxy, carbonyl, HO, lower alkoxy, lower alkylcarbonyloxy, and halo; R1 = aryl or pyridyl optionally substituted by .gtoreq.1 group(s) selected from lower alkyl, lower alkylcarbonyl, lower alkoxy, carbonyl, HO, lower alkoxy, lower alkylcarbonyloxy, and halo; R2 = H, OH, CO2H, lower alkoxy, carbonyl, mono- or di(lower alkyl)carbonyl, amino, or cyclic amino, wherein more than 1 of R2 may be present; X = CH2, O, S, NR3; R3 = (un)substituted lower alkyl, cycloalkyl, (un)substituted aryl, (un)substituted aryl-lower alkyl, (un)substituted heteroaryl, (un)substituted heteroaryl-lower alkyl, lower alkylcarbonyl, lower alkoxy, carbonyl, mono- or di(lower alkyl)carbonyl] or pharmaceutically acceptable salts thereof are prepd. These compds. I have an activity of increasing platelets based on an excellent effect of accelerating megakaryocyte colony formation and are efficacious in treating thrombopenia. Thus, 680 mg 2-methoxyisonicotinic acid and 1.02 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to a soln. of 1.60 g 2-amino-4-(4-fluorophenyl)-5-(4-cyclohexylpiperazino)thiazole in 30 mL THF and stirred at room temp. for 4 days to give N-[5-(4-cyclohexylpiperazi-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-2-methoxyisonicotinamide hydrochloride (II). II in vitro increased the formation of megakaryocyte colonies of human CD34+ cells from 5.2 at 0.3 .mu.M to 19.0 and 34.8 at 1.0 and 3.0 .mu.M, resp.

IT **446065-81-2P**, N-[5-(3-Dimethylamino-pyrrolidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of acylaminothiazole derivs. or salts as promoters of megakaryocyte colony formation for increasing blood platelets and treating thrombopenia)

10/029,871 (patel)

RN 446065-81-2 CAPLUS


CN Benzamide, N-[5-[3-(dimethylamino)-1-pyrrolidinyl]-4-phenyl-2-thiazolyl]-
3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L16 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:554840 CAPLUS
 DN 138:4552
 TI Studies on 2-aminothiazoles: 2-aroylamino-4-[m-(p-chlorobenzenesulfonamido)phenyl]thiazoles
 AU Korgaokar, S. S.; Patel, P. H.; Parekh, H. H.
 CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
 SO Journal of the Institution of Chemists (India) (2001), 73(6), 209-211
 CODEN: JOICA7; ISSN: 0020-3254
 PB Institution of Chemists (India)
 DT Journal
 LA English
 OS CASREACT 138:4552
 AB The title compds. were prepd. by the condensation of 2-amino-4-[m-(p-chlorobenzenesulfonamido)phenyl]thiazole with aroyl chlorides and exhibited antimicrobial activity against bacteria and fungi.
 IT **477334-92-2**
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (prepn. of 2-aroylamino-4-[m-(p-chlorobenzenesulfonamido)phenyl]thiazol
 es)
 RN 477334-92-2 CAPLUS
 CN Benzamide, N-[4-[3-[[(4-chlorophenyl) sulfonyl] amino] phenyl]-2-thiazolyl]-2-hydroxy- (9CI) (CA INDEX NAME)




IT **477334-76-2P 477334-78-4P 477334-82-0P**
477334-83-1P 477334-84-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (prepn. of 2-aroylamino-4-[m-(p-chlorobenzenesulfonamido)phenyl]thiazol
 es)
 RN 477334-76-2 CAPLUS
 CN Benzamide, 2-(acetyloxy)-N-[4-[3-[[(4-chlorophenyl) sulfonyl] amino] phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 477334-78-4 CAPLUS
 CN Benzamide, 3-chloro-N-[4-[3-[[(4-chlorophenyl) sulfonyl] amino] phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 477334-82-0 CAPLUS
CN 2-Naphthalenecarboxamide, N-[4-[3-[[4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-1-hydroxy- (9CI) (CA INDEX NAME)




RN 477334-83-1 CAPLUS
CN 2-Naphthalenecarboxamide, N-[4-[3-[[4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 477334-84-2 CAPLUS
CN Benzamide, N-[4-[3-[[4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-2-methoxy- (9CI) (CA INDEX NAME)



IT **477334-75-1P 477334-77-3P 477334-79-5P**
477334-81-9P 477334-85-3P 477334-86-4P
477334-87-5P 477334-88-6P 477334-89-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 2-arylamino-4-[m-(p-chlorobenzenesulfonamido)phenyl]thiazol
es)
RN 477334-75-1 CAPLUS
CN Benzamide, N-[4-[3-[[4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-
(9CI) (CA INDEX NAME)




RN 477334-77-3 CAPLUS

CN Benzamide, 2-chloro-N-[4-[3-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 477334-79-5 CAPLUS

CN Benzamide, 4-chloro-N-[4-[3-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 477334-81-9 CAPLUS

CN Benzamide, N-[4-[3-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-3,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 477334-85-3 CAPLUS

CN Benzamide, N-[4-[3-[[4-(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 477334-86-4 CAPLUS

CN Benzamide, N-[4-[3-[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 477334-87-5 CAPLUS

CN Benzamide, N-[4-[3-[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 477334-88-6 CAPLUS


CN Benzamide, N-[4-[3-[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 477334-89-7 CAPLUS

CN Benzamide, N-[4-[3-[(4-chlorophenyl)sulfonyl]amino]phenyl]-2-thiazolyl]-4-nitro- (9CI) (CA INDEX NAME)



10/029,871 (patel)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:532380 CAPLUS
 DN 137:325724
 TI Rapid synthesis of optically active poly(amide-imide)s by direct
 polycondensation of aromatic dicarboxylic acid with aromatic diamines
 AU Mallakpour, Shadpour E.; Hajipour, Abdol-Reza; Khoei, Sepideh
 CS Organic Polymer Chemistry Research Laboratory, Isfahan University of
 Technology, College of Chemistry, Esfahan, 84156, Iran
 SO European Polymer Journal (2002), 38(10), 2011-2016
 CODEN: EUPJAG; ISSN: 0014-3057
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB 4,4'-(Hexafluoroisopropylidene)-N,N'-bis(phthaloyl-L-leucine-p-
 amidobenzoic acid) (2) was prepd. from the reaction of
 4,4'-(hexafluoroisopropylidene)-N,N'-bis(phthaloyl-L-leucine) diacid
 chloride with p-aminobenzoic acid. The direct polycondensation reaction
 of monomer (2) with p-phenylenediamine (2a), 4,4'-diaminodiphenylsulfone
 (2b), 2,4-diaminotoluene (2c), 2,6-diaminopyridine (2d), m-phenylene
 diamine (2e), benzidine (2f), 4,4'-diaminodiphenylether (2g) and
 4,4'-diaminodiphenyl methane (2h) was carried out in a medium consisting
 of tri-Ph phosphite, N-methyl-2-pyrrolidone, pyridine, and calcium
 chloride. The homogeneous mixt. was heated at 220.degree. for 1 min under
 nitrogen. The resulting poly(amide-imide)s (PAIs) having inherent
 viscosities 0.27-0.78 dL/g were obtained in high yield and are optically
 active and thermally stable. All of the above polymers were fully
 characterized by IR spectroscopy, elemental analyses and sp. rotation.
 Some structural characterization and phys. properties of this new
 optically active PAIs are reported.
 IT **473554-24-4P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of optically active poly(amide-imide)s from arom. dicarboxylic
 acid with arom. diamines)
 RN 473554-24-4 CAPLUS
 CN Poly[(1,3-dihydro-1,3-dioxo-2H-isoindole-2,5-diyl)[2,2,2-trifluoro-1-
 (trifluoromethyl)ethylidene](1,3-dihydro-1,3-dioxo-2H-isoindole-5,2-
 diyl)[(1S)-1-(2-methylpropyl)-2-oxo-1,2-ethanediyl]imino-1,4-
 phenylenecarbonylimino-2,6-pyridinediyliminocarbonyl-1,4-
 phenyleneimino[(2S)-2-(2-methylpropyl)-1-oxo-1,2-ethanediyl]] (9CI) (CA
 INDEX NAME)

PAGE 1-A



PAGE 1-B



n

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2002:504649 CAPLUS

DN 137:83638

TI Concomitant drugs of p38MAP kinase inhibitors and/or TNF-.alpha. prodn. inhibitors with other specified agents

IN Ohkawa, Shigenori; Naruo, Kenichi; Miwatashi, Seiji

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 278 pp.

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002051442	A1	20020704	WO 2001-JP11353	20011225
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
	JP 2002302458	A2	20021018	JP 2001-392778	20011225
PRAI	JP 2000-396220	A	20001226		
	JP 2001-27572	A	20010202		
OS	MARPAT 137:83638				
AB	Drugs comprising a combination of one or more p38MAP kinase inhibitors and/or TNF-.alpha. prodn. inhibitors with one or more agents selected from the group consisting of: (1) nonsteroidal anti-inflammatory agents; (2) disease-modification antirheumatics; (3) anti-cytokine drugs; (4) immunomodulators; (5) steroidal drugs; and (6) c-JUN N-terminal kinase inhibitors. These concomitant drugs are useful as preventives and remedies for diseases such as rheumatism and arthritis and other diseases. For example, tablets contg. [4-(3,5-dimethylphenyl)-5-(2-phenylmethoxy-4-pyridyl)-1,3-thiazol-2-yl]amine 50 mg/tablet are administered with tablets contg. rofecoxib 5 mg/tablet.				
IT	439914-62-2 439914-64-4 439914-66-6 439914-68-8				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination drugs contg. p38MAP kinase inhibitors and/or TNF-.alpha. prodn. inhibitors with other specified agents)				
RN	439914-62-2 CAPLUS				
CN	3-Pyridinecarboxamide, N-[5-[2-(benzoylamino)-4-pyridinyl]-4-(3-methylphenyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)				

10/029,871 (patel)




RN 439914-64-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-[2-(benzoylamino)-4-pyridinyl]-4-(3-methylphenyl)-2-thiazolyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 439914-66-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-[2-(benzoylamino)-4-pyridinyl]-4-(3-methylphenyl)-2-thiazolyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 439914-68-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-[2-(benzoylamino)-4-pyridinyl]-4-(3-methylphenyl)-2-thiazolyl]-2-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:487561 CAPLUS
 DN 137:63240
 TI Preparation of thiazolyl inhibitors of Tec family tyrosine kinases
 IN Barrish, Joel C.; Das, Jagabandhu; Kanner, Steven B.; Liu, Chunjian;
 Spergel, Steven H.; Witayk, John; Doweiko, Arthur M. P.; Furch, Joseph A.
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 149 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050071	A1	20020627	WO 2001-US49430	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002031139	A5	20020701	AU 2002-31139	20011219
	US 2003069238	A1	20030410	US 2001-27982	20011220
PRAI	US 2000-257830P	P	20001221		
	WO 2001-US49430	W	20011219		

OS MARPAT 137:63240

AB The title compds. [I; Q1 = thiazolyl; Q2 = (un)substituted (hetero)aryl; Z = O, S, NR₄, etc.; R1 = H, OH, SH, etc.; R2, R3 = H, (un)substituted (hetero)aryl, (hetero)arylcarbonyl, etc.; R4 = H, alkyl, aryl, etc.], useful in the treatment of Tec family tyrosine kinase-assocd. disorders such as cancer, immunol. disorders and allergic disorders, were prepd. E.g., a multi-step synthesis of the thiazole II, was given.


IT **439574-86-4P 439574-87-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of thiazolyl inhibitors of Tec family tyrosine kinases)

RN 439574-86-4 CAPLUS


CN Benzamide, N-[5-[[4-(acetylamino)-3-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]thio]-2-thiazolyl]-4-(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



RN 439574-87-5 CAPLUS

CN Benzamide, N-[5-[[4-(acetylamino)-3-[(4-acetyl-1-piperazinyl)carbonyl]phenyl]thio]-2-thiazolyl]-4-(dimethylamino)-(9CI) (CA INDEX NAME)

10/029,871 (patel)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2002:314913 CAPLUS

DN 136:340689

TI Preparation of urea derivatives containing nitrogenous aromatic ring compounds as inhibitors of angiogenesis

IN Funahashi, Yasuhiro; Tsuruoka, Akihiko; Matsukura, Masayuki; Haneda, Toru; Fukuda, Yoshio; Kamata, Junichi; Takahashi, Keiko; Matsushima, Tomohiro; Miyazaki, Kazuki; Nomoto, Kenichi; Watanabe, Tatsuo; Obaishi, Hiroshi; Yamaguchi, Atsumi; Suzuki, Sachi; Nakamura, Katsuji; Mimura, Fusayo; Yamamoto, Yuji; Matsui, Junji; Matsui, Kenji; Yoshiba, Takako; Suzuki, Yasuyuki; Arimoto, Itaru

PA Eisai Co., Ltd., Japan

SO PCT Int. Appl., 699 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032872	A1	20020425	WO 2001-JP9221	20011019
	WO 2002032872	C1	20020926		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095986	A5	20020429	AU 2001-95986	20011019
PRAI	JP 2000-320420	A	20001020		
	JP 2000-386195	A	20001220		
	JP 2001-46685	A	20010222		
	WO 2001-JP9221	W	20011019		
OS	MARPAT 136:340689				
AB	<p>N-aryl or N-heteroarylurea derivs. represented by the general formula Ag-Xg-Yg-Tgl or salts thereof, or hydrates of both [wherein Ag = (un)substituted C6-14 aryl or 5- to 14-membered heterocyclic group; Xg = single bond, O, S, C1-6 alkylene, SO, SO2, (un)substituted NH; Yg = (un)substituted C6-14 aryl, 5- to 14-membered heterocyclic group, C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl-C1-6 alkyl, 5- to 14-membered heteroaryl-C1-6 alkyl, (CH2)gSO2 (g = 1-8), (CH2)faCH:CH(CH2)fb (fa, fb = 0, 1,2,3), etc.; and Tgl = a group of the general formula -Eg-CO-NRgl(Zg) or Q; wherein Eg = a single bond, (un)substituted NH; Rgl = H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 aliph. hydrocarbyl, etc.; Zg = C1-8 alkyl, C3-8 alicyclic hydrocarbyl, C6-14 aryl, etc.; Zgl, Zg2 = (a) a single bond, (b) C1-6 alkylene optionally having .gtoreq.1 atoms selected from O, S, and N in the middle or the terminus of the chain and optionally substituted with oxo, (c) (un)substituted C2-6 alkenyl] are prepd. These compds. are also inhibitors of vascular endothelial growth factor receptor kinase (VEGFR2 kinase) and are useful as antitumor agents against hemangioma, pancreatic cancer, stomach cancer, colon cancer, breast cancer, prostate cancer, lung cancer, brain tumor, leukemia, or ovarian cancer, as cancer metastasis inhibitors, and for the treatment of retina neovascularization, diabetic retinopathy, atherosclerosis, or inflammatory diseases such as osteoarthritis, rheumatoid arthritis, psoriasis, or delayed</p>				

hypersensitivity. Thus, to soln. of 334 mg 4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenylamine in 4 mL DMF were added 0.066 mL pyridine and 0.102 mL Ph chlorocarbonate and stirred at room temp. for 2.5 h to give 330 mg N-[4-[6-(4-benzyloxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea which (260 mg) was hydrogenolyzed over platinum oxide in ethanol overnight to give 160 mg N-[4-[6-(4-hydroxyphenyl)-7-(2-trimethylsilylethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]-2-chlorophenyl]-N'-cyclopropylurea (I). I showed IC50 of 0.02 nM for inhibiting the vascular endothelial growth factor (VEGF)-stimulated sandwich tube formation in vascular endothelial cell.

IT **417714-77-3P 417714-79-5P 417715-00-5P**
417715-01-6P 417715-02-7P 417715-03-8P
417718-10-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of urea derivs. contg. nitrogenous arom. ring compds. as angiogenesis inhibitors for prevention or treatment of diseases)

RN 417714-77-3 CAPLUS


CN 2-Propenoic acid, 3-[2-[(cyclopropylcarbonyl)amino]-4-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]phenoxy]-3-pyridinyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 417714-79-5 CAPLUS


CN Cyclopropanecarboxamide, N-(cyclopropylcarbonyl)-N-[3-ethynyl-4-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 417715-00-5 CAPLUS
 CN Cyclobutanecarboxamide, N-[4-[4-[(2-thiazolylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 417715-01-6 CAPLUS
 CN Cyclopropanecarboxamide, N-[4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 417715-02-7 CAPLUS
 CN Cyclopropanecarboxamide, N-[5-bromo-4-[3-chloro-4-[(cyclopropylamino)carbonyl]amino]phenoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)

10/029,871 (patel)




RN 417715-03-8 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-dichloro-4-
[[(cyclopropylamino) carbonyl] amino] phenoxy]-2-pyridinyl]- (9CI) (CA INDEX
NAME)




RN 417718-10-6 CAPLUS

CN Cyclobutanecarboxamide, N-[4-[4-[[[(4-fluorophenyl) amino] carbonyl] amino] ph
enoxy]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:298302 CAPLUS
 DN 137:232583
 TI Synthesis and antimicrobial activity of 4-oxothiazolidines
 AU Patel, H. D.; Mistry, B. D.; Desai, K. R.
 CS Department of Chemistry, St. Xavier's College, Ahmedabad, 380 009, India
 SO Indian Journal of Heterocyclic Chemistry (2002), 11(3), 233-236
 CODEN: IJCHEI; ISSN: 0971-1627
 PB Prof. R. S. Varma
 DT Journal
 LA English
 OS CASREACT 137:232583
 AB Various 4-oxothiazolidines, e.g. I (R = H), 5-methyl-4-oxothiazolidines, e.g. I (R = Me), and 5-ethanoic acid-4-oxothiazolidines, e.g. I (R = CH₂CO₂H), were prepd. by reacting N-[1-aza-2-(substituted phenyl) vinyl] (2-amino-5-nitro phenyl) carboxamides with thioglycollic acid, thiolactic acid and thiomalic acid resp., and these N-[1-aza-2-(substituted phenyl)vinyl] (2-amino-5-nitro phenyl)carboxamides were synthesized by hydrolysis of N-[1-aza-2-(substituted phenyl)vinyl] (2-acetamido-5-nitro phenyl)carboxamides. Reaction between N-amino-(2-amino-5-nitrophenyl)carboxamide and different aldehydes gives N-[1-aza-2-(substituted phenyl)vinyl] (2-acetamido-5-nitro phenyl) carboxamides. Title compds. were characterized on the basis of elemental and spectral anal. All the newly synthesized compds. were tested for their antibacterial and antifungal activity.
 IT **459790-54-6P 459790-63-7P 459790-72-8P**
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antimicrobial activity of oxothiazolidines)
 RN 459790-54-6 CAPLUS
 CN Benzamide, 2-amino-N-[2-[2-(dimethylamino)-6-hydroxy-4-methylphenyl]-4-oxo-3-thiazolidinyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 459790-63-7 CAPLUS
 CN Benzamide, 2-amino-N-[2-[2-(dimethylamino)-6-hydroxy-4-methylphenyl]-5-methyl-4-oxo-3-thiazolidinyl]-5-nitro- (9CI) (CA INDEX NAME)

10/029,871 (patel)




RN 459790-72-8 CAPLUS
CN 5-Thiazolidineacetic acid, 3-[(2-amino-5-nitrobenzoyl)amino]-2-[2-(dimethylamino)-6-hydroxy-4-methylphenyl]-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:287560 CAPLUS
 DN 137:33479
 TI New Strategy for the Synthesis of Iminoglycitols from Amino Acids
 AU Swaleh, Sauda; Liebscher, Juergen
 CS Institut fuer Chemie, Humboldt-Universitaet Berlin, Berlin, D-12489, Germany
 SO Journal of Organic Chemistry (2002), 67(10), 3184-3193
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 137:33479
 AB A novel strategy for the enantioselective synthesis of polyhydroxypiperidines, e.g. I, which can be considered as imino glycitols or 2,6-dideoxyaza sugars, was developed. .alpha.-Benzolsulfonylamino esters served as a C2N building block while 2-bromo-3-(bromomethyl)oxazoles and -thiazoles contributed a C3-unit to the final piperidine ring. At first a dihydropyridine ring was established via alkylation and bromine-lithium exchange. The keto group of the resulting 5,6-dihydro[1,3]oxazolo- and 5,6-dihydro[1,3]thiazolo[4,5-c]pyridin-7(4H)-ones was reduced and, after alkylation reactions, the azole ring was cleaved, thus providing heteroatom substituents for the target piperidines. Protected 5-amino-3,4-dihydroxy and 5-amino-3-hydroxy-4-thiohydroxypiperidines were obtained in the talose series while Mitsunobu reaction of the intermediates provided access to the altrose series.
 IT **436844-26-7P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of iminoglycitols from amino acids via cyclocondensation reaction)
 RN 436844-26-7 CAPLUS
 CN Benzamide, N,N'-[dithiobis[(3S,4S,5R,6S)-5-methoxy-6-methyl-1-(phenylsulfonyl)-4,3-piperidinediyl]]bis[N-methyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.




RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:283195 CAPLUS
 DN 137:93417
 TI Amplification of chirality in helical supramolecular columns
 AU Brunsfeld, Luc; Lohmeijer, Bas G. G.; Vekemans, Jef A. J. M.; Meijer, E. W.
 CS Laboratory of Macromolecular and Organic Chemistry, Eindhoven University of Technology, Eindhoven, 5600 MB, Neth.
 SO Journal of Inclusion Phenomena and Macrocyclic Chemistry (2001), 41(1-4), 61-64
 CODEN: JIPCF5; ISSN: 1388-3127
 PB Kluwer Academic Publishers
 DT Journal
 LA English
 AB Strong amplification of chirality occurs in dynamic, but highly ordered, helical columns in n-butanol, for which one chiral seed mol. suffices to render a column of 400 mols. to become homochiral. The chiral columns are formed in a thermally dependent stepwise process. The transition from achiral stacks to helical columns is highly cooperative owing to well-defined intermol. interactions. Sergeant and Soldiers measurements allow for the calcn. of the assocn. const. and cooperativity length of the homochiral segments. The Sergeant and Soldiers data on the no. of mols. within a column show a strikingly good match with data obtained from a theor. model describing the self-assembly of the discotic mols. as a function of temp. and concn.
 IT **442690-97-3**
 RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); PROC (Process)
 (soldier; amplification of chirality in helical supramol. columns)
 RN 442690-97-3 CAPLUS
 CN Benzamide, N,N'-[2,2'-bipyridine]-3,3'-diylbis[3,4,5-tris(3,6,9,12,15-pentaoxahexadec-1-yloxy)- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A



PAGE 2-B



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:275966 CAPLUS
 DN 136:294739
 TI Preparation of pyridinyl-substituted benzamides as Apo B secretion inhibitors
 IN Takasugi, Hisashi; Terasawa, Takeshi; Inoue, Yoshikazu; Nakamura, Hideko; Nagayoshi, Akira; Ohtake, Hiroaki; Furukawa, Yoshiro; Mikami, Masafumi; Hinoue, Kazumasa; Ohtsubo, Makoto
 PA Fujisawa Pharmaceutical Co., Ltd., Japan; Daiso Co., Ltd.
 SO PCT Int. Appl., 266 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002028835	A1	20020411	WO 2001-JP8581	20010928
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001092315	A5	20020415	AU 2001-92315	20010928
PRAI	AU 2000-583	A	20001005		
	AU 2001-6666	A	20010727		
	WO 2001-JP8581	W	20010928		


OS MARPAT 136:294739

AB Title compds. I [wherein R1 and R2 = independently alkyl, alkenyl, acyl, amino, (cyclo)alkoxy, aryl(oxy), sulfoxy, mercapto, sulfo, H, halo, NO2, CN, or OH; or R1R2 = a ring; Q1 = N or CH; L = (un)substituted unsatd. 3 to 10-membered heterocyclic group; X = (un)substituted monocyclic (hetero)arylene; Y = (A1)m(A2)n(A4)k; Z = direct bond, CH2, NH, or O; R = H or alkyl; A1 = (un)substituted alkylene or alkenylene; A2 = NR3, CONR3, NHCONH, CO2, O, O(CH2)2NR3, S, SO, or SO2; A4 = alkylene, alkenylene, or alkenylene; R3 = H or suitable substituent; k, m, and n = independently 0 or 1; or a salt thereof] were prepd. as apolipoprotein B (Apo B) secretion inhibitors. For example, to a suspension of N-(4-aminophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide, 2-pyridinylacetic acid.bul.HCl, and HOBT.bul.H2O in CH2Cl2 was added to WSC.bul.HCl, followed by TEA at 5.degree.C. The mixt. was stirred at room temp. for 24 h and worked up to give II. The latter inhibited Apo B secretion by 100% at 10-6 M in HepG2 cells and lowered cholesterol by 83% and triglyceride by 35% after 2 h at a dose of 32 mg/kg in ddY-mice. I are useful for the prophylaxis and treatment of diseases or conditions resulting from elevated circulating levels of Apo B, such as hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus, obesity, coronary heart diseases, myocardial infarction, stroke, restenosis, and Syndrome X.


IT **408368-04-7P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Apo B inhibitor; prepn. of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related

conditions)
 RN 408368-04-7 CAPLUS
 CN Carbamic acid, [6-[[[5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]-2-pyridinyl]oxy]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT **408368-06-9P**, N-[6-[[[6-(Acetylamino)-2-pyridinyl]methoxy]-3-pyridinyl]-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Apo B inhibitor; prepn. of pyridinyl-substituted benzamides as Apo B secretion inhibitors for treatment of obesity, NIDDM, and related conditions)
 RN 408368-06-9 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxamide, N-[6-[[[6-(acetylamino)-2-pyridinyl]methoxy]-3-pyridinyl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

LI6 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:240758 CAPLUS
 DN 136:279477
 TI Preparation of pyrazines as modulators of vascular endothelial growth factor (VEGF) receptor tyrosine kinase.
 IN Kuo, Gee Hong; Connolly, Peter; Prouty, Catherine; Deangelis, Alan; Wang, Aihua; Jolliffe, Linda; Middleton, Steve; Emanuel, Stuart
 PA Ortho-McNeil Pharmaceutical, Inc., USA
 SO PCT Int. Appl., 202 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002024681	A2	20020328	WO 2001-US29175	20010919
	WO 2002024681	A3	20020620		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001094584	A5	20020402	AU 2001-94584	20010919
	US 2003060629	A1	20030327	US 2001-955780	20010919
PRAI	US 2000-233968P	P	20000920		
	WO 2001-US29175	W	20010919		

OS MARPAT 136:279477

AB The present invention also provides pharmaceutical formulations contg. the pyrazine derivs. and methods of use of these formulations as anti-tumor agents and to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis. Title compds. [I; R1 = (substituted) cycloalkyl, (bi)heterocyclyl, (bi)aryl, (bi)heteroaryl; A = N(R4)(CH2)x, O(CH2)x, S(CH2)x, SO2(CH2)x, SO2N(CH2)x, NSO2(CH2)x, N(R4)CONH(CH2)x, etc.; x = 0-4; R4 = H, alkyl, hydroxyalkyl, alkoxyalkyl, arylalkyl, alkenyl, (substituted) aryl, heteroaryl; R2 = (substituted) (bi)heteroaryl; R3 = H, alkyl, alkoxy, alkenyl, alkynyl, heterocyclyl, heterocyclylalkyl, heterocyclylalkoxy, aryl, aralkyl, aralkoxy, OH, hydroxyalkyl, halo, cyano, NO2, amino, (hydroxyalkyl)amino, di(hydroxyalkyl)amino, carbamoyl, acyl, acylalkyl, alkoxy carbonyl, alkoxy carbonylalkyl, acylamino, alkylsulfonyl, alkylsulfonylamino, (substituted) arylsulfonylamino], were prepd. Thus, a mixt. of Et 5-bromonicotinate, bis(tributyltin), Pd(OAc)2, tri-o-tolylphosphine, and Et3N in MeCN was stirred at 95-100.degree. for 22 h. to give 40% Et 5-trimethylstannyl nicotinate. The latter with 2,6-dichloropyrazine, Pd(PPh3)2Cl2, and LiCl were stirred in PhMe at 100.degree. for 23 h to give 60% Et 5-(6-chloropyrazin-2-yl)nicotinate. The latter with 3-chloroaniline, Pd2(dba)3, DPPF, and Cs2CO3 were stirred in dioxane at 110.degree. for 46 h to give Et 5-[6-(3-chlorophenylamino)]pyrazin-2-yl nicotinate. This was converted to 3-[[5-[6-[(3-chlorophenyl)amino]pyrazinyl]-3-pyridinyl]amino]-1-propanol in several steps. The latter inhibited HeLa cell proliferation with IC50 = 4.56 .mu.M.

IT **405940-11-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10/029,871 (patel)


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazines as modulators of vascular endothelial growth factor (VEGF) receptor tyrosine kinase)

RN 405940-11-6 CAPLUS

CN Benzamide, N-[5-[6-[(3-chlorophenyl)amino]pyrazinyl]-3-pyridinyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

NMe₂


L16 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:169229 CAPLUS
 DN 136:224165
 TI Silver halide color photographic light-sensitive film exhibiting low fogging
 IN Kataoka, Emiko; Kagawa, Nobuaki; Tanaka, Tatsuo
 PA Konica Corporation, Japan
 SO Eur. Pat. Appl., 71 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1184717	A2	20020306	EP 2001-121093	20010903
	EP 1184717	A3	20020807		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002148750	A2	20020522	JP 2000-349538	20001116
	US 2002081543	A1	20020627	US 2001-942402	20010830
PRAI	JP 2000-266877	A	20000904		
	JP 2000-349538	A	20001116		
OS	MARPAT 136:224165				
AB	The present invention provides a silver halide photog. light-sensitive film comprising a support having thereon a light-sensitive silver halide emulsion layer comprising a compd. represented by the formula Z-S-X ; wherein Z = group represented by the Formula I (A1, A2, A3, A4, A5 each represent =N-, =N(.fwdarw.O)-, and substituents further defined in the claims), X = H, or Z-S-. The object of the present invention is to provide a silver halide photog. light-sensitive film, comprising mercapto compds. and disulfide compds., which exhibits low fogging, excellent pressure resistance, and excellent sensitivity.				
IT	402726-46-9 402726-48-1 RL: TEM (Technical or engineered material use); USES (Uses) (fog inhibitor; silver halide color photog. light-sensitive film exhibiting low fogging)				
RN	402726-46-9 CAPLUS				
CN	1H-Benzotriazole-5-carboxamide, N,N'-[dithiobis(1-oxido-2,5-pyridinediyl)]bis- (9CI) (CA INDEX NAME)				




RN 402726-48-1 CAPLUS
 CN Benzamide, N,N'-[dithiobis(1-oxido-2,5-pyridinediyl)]bis[4-(2,5-dihydro-5-thioxo-1H-tetrazol-1-yl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



L16 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:130859 CAPLUS
 DN 137:337812
 TI Synthesis of some 4-thiazolidinones as potential antitubercular agents
 AU Joshi, Dharti G.; Oza, Haresh B.; Parekh, Hansa H.
 CS Department of Chemistry, Saurashtra University, Rajkot, 360 005, India
 SO Indian Journal of Heterocyclic Chemistry (2001), 11(2), 145-148
 CODEN: IJCHEI; ISSN: 0971-1627
 PB Prof. R. S. Varma
 DT Journal
 LA English
 AB The starting compd. 5-nitrobenzimidazol-2'-yl-o-benzoyl hydrazide, on treatment with arom. aldehydes yielded the corresponding benzal-(5'-nitrobenzimidazol-2'-yl-o-benzoyl) hydrazines I (R = Ph, 2-ClC₆H₄, 4-HOC₆H₄, etc.). The heterocyclization of I with thioglycolic acid and thiolactic acid furnished the corresponding 2-aryl-3-(5'-nitrobenzimidazol-2'-yl-o-benzamido)-5-H-4-thiazolidinones (3a-o) and 2-aryl-3-(5'-nitrobenzimidazol-2'-yl-o-benzamido)-5-methyl-4-thiazolidinones II (X = CO; R₁ = H, Me, resp.). The compds. were screened for their antitubercular activity against Mycobacterium tuberculosis H37 Rv.
 IT **474301-97-8P 474302-12-0P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of benzimidazoles and thiazolidinones as potential antitubercular agents)
 RN 474301-97-8 CAPLUS
 CN Benzamide, N-[2-[4-(dimethylamino)phenyl]-4-oxo-3-thiazolidinyl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 474302-12-0 CAPLUS
 CN Benzamide, N-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxo-3-thiazolidinyl]-2-(5-nitro-1H-benzimidazol-2-yl)- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2002:126362 CAPLUS

DN 136:177998

TI Thiazole compounds as selective protein kinase C.gamma. inhibitors and sedatives containing them

IN Inaba, Takayuki; Sagawa, Shoichi; Okamoto, Yoshihisa

PA Japan Tobacco, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 113 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002053566	A2	20020219	JP 2000-244080	20000811
PRAI	JP 2000-244080		20000811		
OS	MARPAT 136:177998				

AB Protein kinase C inhibitors contain thiazole compds. I [R1 = H, halo, C1-6 alkyl; R2 = H, (un)substituted C1-6 alkyl (substituents are given); R3, R4 = H, (un)substituted C1-6 alkyl, ORa1 (Ra1 = H, C1-6 alkyl, C1-6 alkylcarbonyl), NRa2Ra3 (Ra2, Ra3 = H, C1-6 alkyl, C1-6 alkoxycarbonyl); NRa2Ra3 may be a ring; R2 and R3 may be bonded together with NCOCR4 to form a (hetero)cycle; X = direct bond, C1-4 alkylene, O, S, CO2, OCO, NRa4, CONRa4, NRa4CO [Ra4 = H, (un)substituted C1-6 alkyl]; ring Hy = (un)substituted heterocyclyl contg. 1-4 O, N, and/or S; Z = H, (un)substituted C1-6 alkyl, C6-14 aryl, C3-7 cycloalkyl, C3-7 cycloalkenyl, heterocyclyl; ring Cy = C6-14 aryl, C3-7 cycloalkyl, heterocyclyl] or their pharmaceutically acceptable salts. Drug compns. and sedatives contg. I or their salts are also claimed. I selectively inhibit protein kinase C .gamma.-isoenzyme. IC50 values of N-[4-[2-(cyclopropylcarbonylamino)-4-methylthiazol-5-yl]thiazol-2-yl]-N-[2-(dimethylamino)ethyl]-2-(2-fluorophenyl)acetamide (II, prepn. given) to PKC.alpha., PHC.beta.II, and PKC.gamma. were 0.8691, 2.9062, and 0.0369 .mu.M, resp. Sedative effect of II was shown in formalin test for rats. Tablets contg. II were also formulated.

IT 400003-30-7P 400003-52-3P 400003-65-8P
 400003-66-9P 400003-67-0P 400003-68-1P
 400004-57-1P 400004-58-2P 400004-59-3P
 400004-60-6P 400004-61-7P 400004-70-8P
 400004-71-9P 400004-72-0P 400004-73-1P
 400004-74-2P 400004-75-3P 400004-76-4P
 400004-78-6P 400004-79-7P 400004-80-0P
 400004-81-1P 400004-86-6P 400004-87-7P
 400004-88-8P 400004-89-9P 400004-91-3P
 400004-94-6P 400004-95-7P 400004-97-9P
 400004-99-1P 400005-05-2P 400005-06-3P
 400005-07-4P 400005-08-5P 400005-09-6P
 400005-10-9P 400005-11-0P 400005-12-1P
 400005-13-2P 400005-14-3P 400005-15-4P
 400005-17-6P 400005-19-8P 400005-20-1P
 400005-21-2P 400005-22-3P 400005-23-4P
 400005-24-5P 400005-25-6P 400005-26-7P
 400005-27-8P 400005-28-9P 400005-29-0P
 400005-30-3P 400005-31-4P 400005-32-5P
 400005-33-6P 400005-34-7P 400005-35-8P
 400005-36-9P 400005-39-2P 400005-40-5P
 400005-41-6P 400005-42-7P 400005-43-8P
 400005-44-9P 400005-45-0P 400005-46-1P


400005-47-2P 400005-48-3P 400005-49-4P
 400005-50-7P 400005-51-8P 400005-52-9P
 400005-53-0P 400005-54-1P 400005-55-2P
 400005-56-3P 400005-57-4P 400005-62-1P
 400005-63-2P 400005-64-3P 400005-65-4P
 400005-66-5P 400005-67-6P 400005-68-7P
 400005-69-8P 400005-70-1P 400005-71-2P
 400005-72-3P 400005-73-4P 400005-74-5P
 400005-75-6P 400005-76-7P 400005-77-8P
 400005-78-9P 400005-79-0P 400005-80-3P
 400005-81-4P 400005-82-5P 400005-83-6P
 400005-84-7P 400005-85-8P 400005-86-9P
 400005-87-0P 400005-88-1P 400005-89-2P
 400005-90-5P 400005-91-6P 400005-92-7P
 400005-93-8P 400005-94-9P 400005-95-0P
 400006-02-2P 400006-03-3P 400006-04-4P
 400006-05-5P 400006-06-6P 400006-11-3P
 400006-12-4P 400006-13-5P 400006-18-0P
 400006-19-1P 400006-20-4P 400006-21-5P
 400006-22-6P 400006-23-7P 400006-24-8P
 400006-25-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of thiazole compds. as selective protein kinase C.gamma.
 inhibitors for sedatives)


RN 400003-30-7 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-
 bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2-fluoro- (9CI) (CA INDEX
 NAME)




RN 400003-52-3 CAPLUS


CN Benzeneacetamide, N-[2'-(benzoylamino)-4'-methyl[4,5'-bithiazol]-2-yl]-
 (9CI) (CA INDEX NAME)



RN 400003-65-8 CAPLUS
 CN Benzeneacetamide, N-[2'-[(4-fluorobenzoyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400003-66-9 CAPLUS
 CN Benzeneacetamide, N-[2'-[(4-methoxybenzoyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400003-67-0 CAPLUS
 CN Benzeneacetamide, N-[2'-[[4-(1,1-dimethylethyl)benzoyl]amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)

10/029,871 (patel)




RN 400003-68-1 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopentylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-57-1 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopentylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-58-2 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(2-fluorobenzoyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-59-3 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(3-fluorobenzoyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-60-6 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(4-fluorobenzoyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-61-7 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[4'-methyl-2'-[[4-(trifluoromethyl)benzoyl]amino][4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)


10/029,871 (patel)




RN 400004-70-8 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclohexylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)



RN 400004-71-9 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[4'-methyl-2'-[[4-methylcyclohexyl)carbonyl]amino][4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-72-0 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-73-1 CAPLUS
 CN Cycloheptanecarboxamide, N-[2-[[[3-(benzoylamino)phenyl]acetyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)


10/029,871 (patel)




RN 400004-74-2 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[[4-methoxycyclohexyl]carbonyl]amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI)
 (CA INDEX NAME)




RN 400004-75-3 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-76-4 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclobutylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-78-6 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopentylcarbonyl)amino][4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-79-7 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopentylcarbonyl)amino][4,5'-bithiazol]-2-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 400004-80-0 CAPLUS
 CN Cyclopentanecarboxamide, N-[2'-(acetalamino)-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)



RN 400004-81-1 CAPLUS
 CN Cyclohexanecarboxamide, N-[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-86-6 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400004-87-7 CAPLUS
 CN Benzeneacetamide, 3-[(cyclohexylcarbonyl)amino]-N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)

10/029,871 (patel)




RN 400004-88-8 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 400004-89-9 CAPLUS

CN Benzeneacetamide, 3-[(cyclohexylcarbonyl)amino]-N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]-N-methyl- (9CI) (CA INDEX NAME)




RN 400004-91-3 CAPLUS


CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 400004-94-6 CAPLUS
CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-
bithiazol]-2-yl]-3-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-N-methyl-
(9CI) (CA INDEX NAME)




RN 400004-95-7 CAPLUS
CN Benzeneacetamide, 3-[(cyclohexylcarbonyl)amino]-N-[2'-
[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-methyl-
(9CI) (CA INDEX NAME)



10/029,871 (patel)


RN 400004-97-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-[[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 400004-99-1 CAPLUS

CN Benzeneacetamide, 3-[(cyclohexylcarbonyl)amino]-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]- (9CI) (CA INDEX NAME)




RN 400005-05-2 CAPLUS


CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 400005-06-3 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-methyl-3-(1-oxo-2(1H)-isoquinolinyl)- (9CI) (CA INDEX NAME)




RN 400005-07-4 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-3-[(3-fluorobenzoyl)amino]-N-methyl- (9CI) (CA INDEX NAME)



10/029,871 (patel)


RN 400005-08-5 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-
 bithiazol]-2-yl]-3-[(4-fluorobenzoyl)amino]-N-methyl- (9CI) (CA INDEX
 NAME)




RN 400005-09-6 CAPLUS

Benzenacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-
bithiazol]-2-yl]-3-(3,4-dihydro-1-oxo-2(1H)-isoquinolinyl)-N-methyl- (9CI)
(CA INDEX NAME)



RN 400005-10-9 CAPLUS


Benzenacetamide, 3-amino-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 400005-11-0 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-.alpha.-methoxy-N-methyl-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 400005-12-1 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-.alpha.-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 400005-13-2 CAPLUS


CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-.alpha.-methoxy-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400005-14-3 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-[2-[[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]methylamino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 400005-15-4 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 400005-17-6 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 400005-19-8 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[3-[2-[[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]methylamino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400005-20-1 CAPLUS
 CN Benzeneacetamide, .alpha.-amino-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 400005-21-2 CAPLUS

CN Benzeneacetamide, .alpha.-(acetyloxy)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 400005-22-3 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-.alpha.-hydroxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 400005-23-4 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]-.alpha.-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 400005-24-5 CAPLUS


CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-.alpha.-methoxy-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400005-25-6 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Me₂N--(CH₂)₃--NPh--CH₂--C
O


RN 400005-26-7 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino][4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 400005-27-8 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-28-9 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[4-(dimethylamino)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-29-0 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[4-(dimethylamino)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-30-3 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[4-(dimethylamino)butyl]-.alpha.-methoxy-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/029,871 (patel)



● HCl

RN 400005-31-4 CAPLUS



CN 3-Thiopheneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl

RN 400005-32-5 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/029,871 (patel)

RN 400005-33-6 CAPLUS


CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-34-7 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-.alpha.-methoxy-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 400005-35-8 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/029,871 (patel)



● HCl

RN 400005-36-9 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]4,5'-bithiazol-2-yl]-N-[3-(dimethylamino)propyl]-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 400005-39-2 CAPLUS



CN 1H-Indole-3-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol-2-yl]-N-[3-(dimethylamino)propyl]-, monohydrochloride (9CI)
(CA INDEX NAME)

10/029,871 (patel)




● HCl

RN 400005-40-5 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 400005-41-6 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(1-piperidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-42-7 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-43-8 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(1-piperidinylethyl)]-, monohydrochloride (9CI) (CA INDEX NAME)

10/029,871 (patel)




● HCl

RN 400005-44-9 CAPLUS
 CN 1H-Indole-3-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 400005-45-0 CAPLUS
 CN 2-Thiopheneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 400005-46-1 CAPLUS
 CN 3-Thiopheneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400005-47-2 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-.alpha.-methoxy-, monohydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 400005-48-3 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

10/029,871 (patel)




RN 400005-49-4 CAPLUS
 CN 1H-Indole-3-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 400005-50-7 CAPLUS
 CN 3-Benzofuranacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-1-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/029,871 (patel)



● HCl


RN 400005-51-8 CAPLUS
CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 400005-52-9 CAPLUS
CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-4-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)

10/029,871 (patel)




RN 400005-53-0 CAPLUS
 CN Benzeneacetamide, 3-bromo-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-54-1 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-.alpha.-(dimethylamino)-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/029,871 (patel)




● HCl

RN 400005-55-2 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 400005-56-3 CAPLUS
 CN 3-Thiopheneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-57-4 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-62-1 CAPLUS
 CN 1H-Indole-3-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 400005-63-2 CAPLUS
CN 3-Thiopheneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 400005-64-3 CAPLUS
CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




RN 400005-65-4 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3-nitro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-66-5 CAPLUS
 CN Benzeneacetamide, 3,4-dichloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-67-6 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-4-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-68-7 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-69-8 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-70-1 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-71-2 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-72-3 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-73-4 CAPLUS


CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3,5-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-74-5 CAPLUS


CN 1-Piperidineacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-.alpha.-phenyl-, monohydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 400005-75-6 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI)
 (CA INDEX NAME)



● HCl


RN 400005-76-7 CAPLUS
 CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 400005-77-8 CAPLUS


CN Benzeneacetamide, 2,6-dichloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 400005-78-9 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-79-0 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-4-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-80-3 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2,4,6-trimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN	400005-81-4	CAPLUS
CN	Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(1H-imidazol-1-yl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)	




● HCl

RN 400005-82-5 CAPLUS
CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(4-methyl-1-piperazinyl)propyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 400005-83-6 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2,3-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 400005-84-7 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-85-8 CAPLUS


CN Benzeneacetamide, 2-bromo-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-86-9 CAPLUS

CN 1,3-Benzodioxole-5-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/029,871 (patel)



● HCl

RN 400005-87-0 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 400005-88-1 CAPLUS

CN Benzo[b]thiophene-3-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/029,871 (patel)



● HCl

RN 400005-89-2 CAPLUS


CN Benzeneacetamide, 2-chloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 400005-90-5 CAPLUS

CN Benzeneacetamide, 2,4-dichloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-91-6 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3,4-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-92-7 CAPLUS


CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-93-8 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2,6-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400005-94-9 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-3,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400005-95-0 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2,5-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-02-2 CAPLUS
 CN Benzeneacetamide, N-(2-aminoethyl)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-2-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-03-3 CAPLUS

CN Benzeneacetamide, N-(2-aminoethyl)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-2,6-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-04-4 CAPLUS

CN Benzeneacetamide, N-(2-aminoethyl)-2-chloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-05-5 CAPLUS

CN Benzeneacetamide, N-(2-aminoethyl)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-2,4-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-06-6 CAPLUS

CN Benzeneacetamide, N-(2-aminoethyl)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 400006-11-3 CAPLUS
CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-2-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-12-4 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-13-5 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[3-(dimethylamino)propyl]-2,6-difluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-18-0 CAPLUS

CN [1,1'-Biphenyl]-4-acetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-19-1 CAPLUS
 CN 1-Naphthaleneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● HCl

RN 400006-20-4 CAPLUS
 CN Benzeneacetamide, 3-(acetylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-21-5 CAPLUS
 CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-2-nitro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-22-6 CAPLUS

CN Benzeneacetamide, 2-chloro-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(dimethylamino)ethyl]-6-fluoro-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-23-7 CAPLUS

CN Benzeneacetamide, N-(2-aminoethyl)-3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 400006-24-8 CAPLUS

CN Benzeneacetamide, N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-2-fluoro-N-[2-(methylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 400006-25-9 CAPLUS

CN Benzeneacetamide, 3-(benzoylamino)-N-[2'-[(cyclopropylcarbonyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]-N-[2-(methylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




IT 400006-33-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of thiazole compds. as selective protein-kinase C.gamma. inhibitors for sedatives)

RN 400006-33-9 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[[2-(dimethylamino)ethyl]amino]-4'-methyl[4,5'-bithiazol]-2'-yl]- (9CI) (CA INDEX NAME)



L16 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2001:904182 CAPLUS

DN 136:37500

TI Preparation of thiophene derivatives as anticancer agents

IN Luzzio, Michael Joseph; Marx, Matthew Arnold; Yang, Bingwei Vera

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001094353	A1	20011213	WO 2001-IB766	20010502
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
	EP 1287001	A1	20030305	EP 2001-925786	20010502
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
	US 2002042409	A1	20020411	US 2001-873555	20010604
FRAI	US 2000-209686P	P	20000606		
	WO 2001-IB766	W	20010502		
OS	MARPAT 136:37500				
AB	The prepn. of compds. of the formula [I; X = N, CH, C(CN); Y = N, CH, CF, N.fwdarw.O; R1 = H, (C1-6)alkyl; R2 = 5 to 13 membered heterocycle, optionally substituted by 1 to 5 substituents; R3 = C(O)N(alkyl)2, CO2(alkyl), etc.] or pharmaceutically acceptable salts and hydrates thereof, where prepd. Thus, a multistep synthesis of 100% 7-chloro-thieno[3,2-b]pyridine-2-carboxylic acid amide was demonstrated. The compds. are useful for inhibiting abnormal cell growth, including cancer.				
IT	380236-34-0P 380236-58-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of thiophene derivs. as anticancer agents)				
RN	380236-34-0 CAPLUS				
CN	Cyclobutanecarboxamide, N-[1-[[7-[(2-methyl-1H-indol-5-yl)amino]thieno[3,2-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)				

10/029,871 (patel)




RN 380236-58-8 CAPLUS

CN Cyclobutanecarboxamide, N-methyl-N-[1-[[7-[(2-methyl-1H-indol-5-yl)amino]thieno[3,2-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



RN 380236-58-8 CAPLUS

CN Cyclobutanecarboxamide, N-methyl-N-[1-[[7-[(2-methyl-1H-indol-5-yl)amino]thieno[3,2-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2003 ACS

AN 2001:904182 CAPLUS

DN 136:37500

TI Preparation of thiophene derivatives as anticancer agents

IN Luzzio, Michael Joseph; Marx, Matthew Arnold; Yang, Bingwei Vera

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001094353	A1	20011213	WO 2001-IB766	20010502
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1287001	A1	20030305	EP 2001-925786	20010502
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US	2002042409	A1	20020411	US 2001-873555	20010604
PRAI	US 2000-209686P	P	20000606		
	WO 2001-IB766	W	20010502		
OS	MARPAT 136:37500				
AB	The prepn. of compds. of the formula [I; X = N, CH, C(CN); Y = N, CH, CF, N.fwdarw.O; R1 = H, (C1-6)alkyl; R2 = 5 to 13 membered heterocycle, optionally substituted by 1 to 5 substituents; R3 = C(O)N(alkyl)2, CO2(alkyl), etc.] or pharmaceutically acceptable salts and hydrates thereof, where prepd. Thus, a multistep synthesis of 100% 7-chloro-thieno[3,2-b]pyridine-2-carboxylic acid amide was demonstrated. The compds. are useful for inhibiting abnormal cell growth, including cancer.				
IT	380236-34-0P 380236-58-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of thiophene derivs. as anticancer agents)				
RN	380236-34-0 CAPLUS				
CN	Cyclobutanecarboxamide, N-[1-[[7-[(2-methyl-1H-indol-5-yl)amino]thieno[3,2-b]pyridin-2-yl]carbonyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)				

L16 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2003 ACS
 AN 2001:816614 CAPLUS
 DN 135:357944
 TI Preparation of nitrophenylcarboxamide derivatives as peroxisome
 proliferator-activated receptor (PPAR) .gamma. modulators
 IN Amemiya, Yoshiya; Wakabayashi, Kenji; Takaishi, Sachiko; Fukuda, Chie
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 186 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083427	A1	20011108	WO 2001-JP3655	20010426
	W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, US, ZA RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	AU 2001052612	A5	20011112	AU 2001-52612	20010426
	EP 1277729	A1	20030122	EP 2001-925984	20010426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
	JP 2002332266	A2	20021122	JP 2001-130983	20010427
	NO 2002005142	A	20021227	NO 2002-5142	20021025
PRAI	JP 2000-129565	A	20000428		
	JP 2001-60366	A	20010305		
	WO 2001-JP3655	W	20010426		
OS	MARPAT 135:357944				
AB	The title compds. I [A represents Ph, etc.; B represents aryl, etc.; X represents oxygen, etc.; and n is 0 or 1] are prepd. I are remedies for involutional osteoporosis which inhibit the accelerated differentiation of adipocytes and promote the formation and differentiation of osteoblasts from stem cells; I are also remedies for diabetes. In an in vitro test for PPAR .gamma. modulating activity, N-[4-(4-methylpiperazin-1- ylcarbonyl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide showed IC50 value of 0.6 nM.				
IT	372095-56-2P 372095-97-1P 372096-23-6P 372096-24-7P 372096-38-3P 372096-39-4P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of nitrophenylcarboxamide derivs. as PPAR .gamma. modulators)				
RN	372095-56-2 CAPLUS				
CN	Carbamic acid, [4-[2-[(2-chloro-5-nitrobenzoyl)amino]-4-thiazolyl]phenyl]- , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				



RN 372095-97-1 CAPLUS


10/029,871 (patel)

CN Carbamic acid, [3-[2-[(2-chloro-5-nitrobenzoyl)amino]-4-thiazolyl]phenyl]-
, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 372096-23-6 CAPLUS

CN Benzamide, 2-chloro-N-[4-[4-[(methylsulfonyl)amino]phenyl]-2-thiazolyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 372096-24-7 CAPLUS

CN Benzamide, N-[4-[4-(acetamino)phenyl]-2-thiazolyl]-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



RN 372096-38-3 CAPLUS


CN Benzamide, N-[4-[3-(acetamino)phenyl]-2-thiazolyl]-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



10/029,871 (patel)

RN 372096-39-4 CAPLUS

CN Benzamide, 2-chloro-N-[4-[3-[(methylsulfonyl)amino]phenyl]-2-thiazolyl]-5-nitro- (9CI) (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/029,871 (patel)

=> d his

(FILE 'HOME' ENTERED AT 08:02:09 ON 13 MAY 2003)

FILE 'REGISTRY' ENTERED AT 08:02:14 ON 13 MAY 2003

L1 SCREEN 1840
L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3 STRUCTURE UPLOADED
L4 QUE L3 AND L1 NOT L2
L5 0 S L4 SSS SAM
L6 SCREEN 1840
L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8 STRUCTURE UPLOADED
L9 QUE L8 AND L6 NOT L7
L10 SCREEN 1840
L11 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L12 STRUCTURE UPLOADED
L13 QUE L12 AND L10 NOT L11
L14 0 S L13 SSS SAM
L15 376 S L13 SSS FUL

FILE 'CAPLUS' ENTERED AT 08:12:17 ON 13 MAY 2003

L16 27 S L15

FILE 'CAOLD' ENTERED AT 08:14:05 ON 13 MAY 2003

=> s 115

L17 0 L15